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1. Summary 
Aim: To illustrate diabetes care in Rwanda and to compare childhood diabetes care in Rwanda, Sub-
Saharan Africa and Norway with guidelines from International Society for Pediatric and Adolescent 
Diabetes (ISPAD). 
Methods: Part 1 and part 2: Literature review of diabetes care with focus on children with type 1 
diabetes in Sub-Saharan Africa and Norway based on a non-systematic search on PubMed and on a 
standardized electronic questionnaire quality assessed with a local informant in Norway at Ullevål 
University Hospital (UUH). Part 3: A partly personal observational study from University Teaching 
Hospital (UTHB) in Rwanda based on eight pediatric case reports and an interview with a local 
informant. 
Results: Norway has among the highest incidences in the world of type 1 diabetes in the age group 0-
14 years (36 per 100 000 PYR), Rwanda has among the lowest (0.3 per 100 000 PYR). Type 1 
diabetes constitutes the major subtype of diabetes among children and adolescents at UUH (92%) and 
UTHB (100%). The mean age at onset was 8.1 years at UUH and 10.2 years at UTHB. All children 
(100%) at UTHB had diabetic ketoacidosis at onset compared to 25 % at UUH. The most common 
administration form at UUH was continuous subcutaneous insulin infusion subsequently the pen and 
all subjects followed a multiple daily injection regime. At UTHB all patients used syringes and 
injections twice daily. Survival rate in Norway is 94.6% after 25 years. Type 1 diabetes in Rwanda 
reduces life expectancy with 20 years (from 58 years to 30 to 35 years). Having diabetes in a 
developing country as Rwanda implies a great financial burden on the family and outcome is often 
poor. Insulin availability remains a problem and urgent international financial support is needed. Re-
hospitalized patients were admitted to hospital with multiple organ pathologies, but no registration of 
direct diabetic complications was done. Currently, there is no official diabetes registry or guidelines of 
diabetes care in Rwanda.  
Conclusion: Diabetes is still a neglected disease in Rwanda, though, greater awareness and knowledge 
is rising. Implementing of current ISPAD guidelines is not possible in Rwanda emphasizing the 
importance of new guidelines directed towards developing countries. 
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2. Abbreviations 
ACR Albumin Creatinine Ratio 
ADA American Diabetes Association 
AER Albumin Excretion Rate 
AIDS Acquired Immunodeficiency Syndrome 
BG Blood Glucose 
CMR Child Mortality Rate 
ECG Electrocardiogram 
EDIC Epidemiology of Diabetes Interventions and Complications study 
EUR Euro 
DCCT The Diabetes Control and Complications Trial 
DERI Diabetes Epidemiology Research International study 
DIAMOND Diabetes Mondiale Study 
DKA Diabetic Ketoacidosis 
DM Diabetes Mellitus 
DN Diabetic Nephropathy 
DR Diabetic Retinopathy 
EDIC Epidemiology of Diabetes Interactions and Complications study 
ESRD End Stage Renal Disease 
EURODIAB Europe and Diabetes study 
GDP Gross Domestic Product 
GFR Glomerular Filtration Rate 
FPG Fasting Plasma Glucose  
HbA1c Hemoglobin A 1 C 
HIV Human Immunodeficiency Virus 
IDDM  Insulin-Dependent Diabetes Mellitus 
IDF International Diabetes Federation 
IGT Impaired Glucose Tolerance 
IFG Impaired Fasting Glucose 
IHD Ischemic Heart Disease 
ISPAD International Society of Pediatric and Adolescence Diabetes 
JVP Jugular Vein Pressure 
MDI Multiple Daily Injections 
MODY Maturity Onset Diabetes of the Young 
MRDM Malnutrition-related Diabetes Mellitus 
NCDR Norwegian Childhood Diabetes Registry 
NIDDM Non-Insulin-Dependent Diabetes Mellitus 
NPH Neutral Protamine Hagedorn 
OGTT Oral Glucose Tolerance Test 
OPC Outpatient Clinic 
PDR Proliferative Diabetic Retinopathy 
p-glu Plasma Glucose 
PYR Patient-Years 
RwF Rwandese Franc 
s.c Subcutaneous 
SSA Sub-Saharan Africa 
T1D Type 1 Diabetes 
T2D Type 2 Diabetes 
TSH Thyroid Stimulating Hormone 
UUH Ullevål University Hospital 
UKPDS United Kingdom Prospective Diabetes study 
UTHB University Teaching Hospital of Butare 
WHO World Health Organization 
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3. Introduction 
Diabetes Mellitus (DM) is a group of metabolic diseases characterized by chronic hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both [1,2]. Diabetes has been recognized 
since antiquity and its symptoms, which include excessive drinking and frequent urination, were noted 
on Egyptian papyrus in about 1550 BC (later recognized by George Ebers) [3]. The role of the 
pancreas in diabetes was described in 1889 by Joseph von Mering and Oscar Minkowski [4], 
eventually leading to the discovery of insulin in 1921 by Sir Frederick Grant Banting and Charles 
Herbert Best [5]; this changed the outcome of diabetes dramatically. Before the discovery of insulin, 
patients with type 1 diabetes (T1D) became emaciated and usually died within one or two years after 
diagnosis [6]. The first patient was treated in 1922 and The New York Times declared that insulin 
could cure diabetes [7]. Mortality rates in patients younger than 20 years declined dramatically a few 
years later [6]. However, with the introduction of insulin patients lived longer and complications 
became more apparent. Renal failure, cardiac arrest, blindness, gangrene and other complications 
typically shortened life expectancy by 15 years [8].  
Until the 1950s physicians did not distinguish between T1D and type 2 diabetes (T2D). Still, they 
recognized a difference between what they called ―acute‖ and ―chronic‖ [7]. Insulin had a more 
dramatic effect on individuals with the ―acute‖ form, which affected primarily young children. The 
―chronic‖ form tended to affect the middle-age, elderly obese and this form was insensitive to insulin. 
Currently, the ―acute‖ form represents T1D and the ―chronic‖ form represents T2D. In 1999, the 
World Health Organization (WHO) suggested a subdivision into four main groups of diabetes; T1D, 
T2D, gestational diabetes and other specific types (heterogenic group) [9], the latter includes diabetes 
caused by: genetic defects in beta-cell function, frequently called ―Maturity Onset of the Young‖ 
(MODY), genetic defects in insulin action, genetic syndromes associated with diabetes and diabetes 
secondary to other conditions, such as pancreatitis and cystic fibrosis. 
Despite increased availability of insulin, worldwide mortality is not declining and both prevalence and 
incidence appears to be increasing. Mortality is an important measure of population health and is often 
used to assign priorities in health interventions. The International Diabetes Federation (IDF) estimated 
that four million deaths in the 20-79 age group may be attributable to diabetes in 2010, accounting for 
almost 7% of global mortality, equal to many infectious diseases like Human Immunodeficiency Virus 
(HIV)/Acquired Immunodeficiency Syndrome (AIDS) [10,11]. Deaths attributable to diabetes in a 
global perspective have been challenging to estimate because one third of the countries of the world do 
not have reliable data. Most of these are countries in Sub-Saharan Africa (SSA) [10]. Routinely 
reported statistics based on death certificates can underestimate mortality by threefold because 
individuals often die of cardiovascular and renal disease and not from a cause uniquely related to 
diabetes [12]. Diabetes is increasing most rapidly in developing countries, where industrialization and 
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urbanization have led to the adoption of a western lifestyle. According to WHO around 220 million 
people had diabetes in 2011 and the rate is predicted to double by 2030 [13].  
4. Aims 
The aim of this thesis is to illustrate diabetes care in Rwanda and to compare childhood diabetes care 
in Sub-Saharan Africa and Norway according to guidelines from International Society for Pediatric 
and Adolescent Diabetes (ISPAD). All forms of diabetes will be discussed, however, the main focus of 
the thesis will be on pediatric T1D. Relatively few studies on diabetes have been done in SSA earlier 
and I hope this study can contribute to an increase in the knowledge and awareness of diabetes in SSA.  
Additionally, this thesis is part of a larger study called ―Diabetes in children; a global comparative 
study‖. Medical students in this project go to various countries in the world to observe and study 
diabetes care based on a standardized questionnaire.  
5. Methods  
This thesis is based on a literature review of diabetes care in SSA and Norway. Included is an 
observational study about Rwanda, based on eight pediatric case reports from a university hospital in 
Rwanda.  
A non-systematic search on PubMed was performed to find published literature on diabetes in SSA 
and Norway. Data from Norway was additionally provided by the Norwegian Childhood Diabetes 
Registry (NCDR) and a local informant, diabetic nurse Siv Janne Kummernes at Ullevål University 
Hospital (UUH) in Oslo. I observed outpatient clinic (OPC) consultations at UUH together with 
paediatrician and endocrinologist Dr. Torild Skrivarhaug. Eight case reports were retrieved from 
University Teaching Hospital of Butare (UTHB) to gather information on diabetes care in Rwanda in 
addition to my personal experience from spending seven weeks at this hospital (five weeks at 
paediatrics and two weeks at internal medicine) and an interview with a paediatrician at this hospital, 
Professor JWO Iraka. 
We designed a standardized electronic questionnaire (appendix 1) largely based on international 
guidelines posted by ISPAD and American Diabetes Association (ADA). The questionnaire was 
divided into two parts. The first part was designed to map diabetes in children at a national or regional 
level. This part included figures on: incidence, prevalence, mortality, complications, patient 
organizations, demographics and economy. The first part of the questionnaire was based on 
information available on the internet and other available sources. The information was then quality 
assessed with the local informant. The second part was designed to map how children with diabetes 
are followed up at the local hospital/treatment centre. The interview contained multiple open, 
qualitative questions.  
 Lene Sleire  
Page 8 of 65 
   
6. PART 1: Literature review 
6.1. Type 1 Diabetes 
Epidemiology for type 1 diabetes 
T1D is the most common endocrine and metabolic disease in childhood. In 2010, the total child 
population of the world (0–14 years) was estimated to be 1.9 billion, of whom 0.02% have diabetes 
[9]. This means that approximately 480,000 children around the world have diabetes with 76,000 new 
cases diagnosed each year reflecting an annual incidence increase of 3% [9]. Two international 
collaborative projects, the Diabetes Mondiale study (DIAMOND) [14] and the Europe and Diabetes 
study (EURODIAB) [15] have monitored trends in incidence. There is a worldwide increase in both 
low incidence countries and high incidence countries, with the strongest increase in the former [9]. 
Studies are contradictory with the overall increased incidence is a result of clinical manifestation at a 
younger age, rather than a worldwide increase in the lifetime number of patients with the disease [16-
21]. Especially in African countries it is difficult to conclude as long as child mortality is high and it is 
likely that many children die before clinical manifestations of diabetes can be monitored.  
T1D is diagnosed in all age groups with a peak incidence around puberty (10-14 years) [14], the 
incidence increases progressively with age towards this peak. In a study from Sweden [20] the peak 
appeared in a younger age group (5-9 years old), this support the observation that diabetes is more 
frequently diagnosed in younger age groups [18-21]. T1D incidence in the age group 0-14 years varies 
greatly between countries, within countries and between different ethnic populations [14]. Finland has 
the highest incidence rate of 57.6 per 100 000 patient-years (PYR) [1,22] and China and Japan has the 
lowest with 0.1 and 2.4 per 100 000 PYR [23,24]. Norway is a high incidence country with 36 per 
100 000 PYR [25], unfortunately data for Rwanda is not available. 
There is an enormous (30-fold) international variation in the frequency of the T1D. This difference 
also accounts for variation in mortality rate between developed and developing countries, but also 
between developed countries as well [26-28]. Figures from the Diabetes Epidemiology Research 
International study (DERI) [26,27] demonstrates that individuals with T1D in Sofia, Bulgaria, were 
ten times more likely to die than those in Norway prior to the age of 25 years. In developed countries 
patients with T1D have a two to tenfold increased risk of dying compared to baseline populations. In 
developing countries some patients die within a few years [28].  
Etiology and pathogenesis for type 1 diabetes 
T1D is characterized by selective destruction of the insulin producing pancreatic islet β-cells, usually 
leading to absolute insulin deficiency; the etiology is not completely understood. Serological markers 
as islet cell antibodies, glutamic acid decarboxylation, islet antigen 2, islet antigen 2 beta and insulin 
autoantibodies of an autoimmune pathological process, are present in 85-90% of individuals when 
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fasting hyperglycemia is detected [29,30]. Susceptibility is determined by multiple genes and 
haplotypes [31,32]. Although family aggregation accounts for approximately 10 % of cases of T1D, 
there is no recognizable pattern of inheritance [33]. Environmental triggers which initiate and drive 
beta cell destruction still remain largely unknown [34]. 
The clinical presentations of T1D vary according to the rate of beta cell destruction. In general, the 
rate is rapid in infants and children and slower in adults and the presenting symptoms vary 
accordingly. The classic history of new onset T1D includes increasing polyuria, polydipsia, excessive 
thirst and weight loss over two to six weeks; especially in young patients the first manifestation can be 
ketoacidosis [1,35].  
Symptoms usually appear when more than 90 % of the β-cells have been destroyed [36]. As insulin is 
the mediator for glucose uptake into the cells, lack of insulin will gradually lead to hyperglycemia and 
diabetic ketoacidosis (DKA). Increased blood glucose (BG) can be asymptomatic but as the 
hyperglycemia progresses it will exceed the renal threshold (10mmol/l) and result in: osmotic diuresis, 
dehydration, loss of electrolytes and vomiting leading to induced release of stress hormones. Stress 
hormones, glucagon, cortisol and growth hormone will increase insulin resistance and further 
aggravate the hyperglycemia, hyperketonemia and hyperosmolality. Hyperketonemia evolves as the 
tissues metabolize fatty acids instead of glucose and ketones accumulate in the blood producing 
ketosis, ultimately leading to coma and death.  
Diabetic ketoacidosis 
Clinical manifestations of DKA are: dehydration, rapid and deep sighing (Kussmaul respiration), 
nausea, vomiting, abdominal pain mimicking an acute abdomen, progressive obtundation and loss of 
consciousness, increased leukocyte count with left shift, non-specific elevation of serum amylase and 
fever when infection is present [37]. Biochemical criteria for diagnosis of DKA according to ISPAD 
are [38]: 
 Hyperglycemia (BG >11 mmol/L [≈200 mg/dL]). 
 Venous pH <7.3 or bicarbonate <15 mmol/L. 
 Ketonemia and ketonuria. 
6.2. Type 2 Diabetes  
Epidemiology for type 2 diabetes 
In most western countries T1D accounts for more than 90 % of the cases among children and 
adolescents, while T2D affects predominantly the elderly [20,39]. In contrast, the incidence of T2D in 
young onset diabetes is nearly 50% in Taiwan [40] and more than 90 % in Hong Kong [41]. In 
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contrast to T1D, T2D is associated with a strong family history of diabetes (80% having parents with 
DM) [1].  
Not all patients present as a classic T2D picture in overweight and obese patients. One third of the 
patients with T2D present a picture of DKA [42], which is often misdiagnosed as T1D. The diagnosed 
autoimmune ―T2D‖ is most likely autoimmune T1D in overweight and obese individuals with 
underlying insulin resistance (15 to 40% have T1D-associated auto-antibodies) [43]. Hemoglobin A 1 
c (HbA1c) concentrations are significant higher in these individuals, β-cell function is significantly 
less and they require insulin treatment sooner. Diabetes autoantibody testing should be considered in 
all pediatric patients with the clinical diagnosis of T2D, because of the high frequency of islet cell 
autoimmunity in otherwise ‗‗typical‘‘ T2D, as antibodies will indicate an earlier need for insulin [43]. 
Etiology and pathogenesis for type 2 diabetes 
T2D is characterized by insulin resistance in peripheral tissues, but may range from predominantly 
insulin resistance with relative insulin deficiency, to a predominantly secretory defect with or without 
insulin deficiency. Insulin resistance is an impaired response to the physiologic effects of insulin, and 
diabetes is only one of the manifestations of the insulin resistance syndrome commonly associated 
with T2D. Other manifestations of this syndrome include obesity, nephropathy, hypertension, 
dyslipidemia, ovarian hyperandrogenism and non-alcoholic fatty liver disease [43,44].  
Treatment for type 2 diabetes 
The treatment for T2D is given according to the severity of the situation determined by symptoms, 
hyperglycemia and presence or absence of ketosis. Asymptomatic children can be treated non-
pharmaceutical but if normalized fasting BG is not achieved with dietary modifications and lifestyle 
changes, pharmacotherapy will be necessary. Initial pharmaceutical treatment involves oral tablets 
designed to increase insulin sensibility,  suppress hepatic glucose production, enhance peripheral 
glucose uptake, increases fatty acid oxidation, and decreases absorption of glucose from the 
gastrointestinal tract. The final stage in T2D treatment is insulin therapy as for T1D patients. 
6.3. Diagnostic criteria 
Different sets of diagnostic criteria for diabetes mellitus have been reported by WHO/IDF (2006) [45] 
and ISPAD (2009) [1]. In both sets the criteria applies for T1D, T2D and other specific types. ISPAD 
recommendations are directed especially towards children and adolescents; based upon the WHO 
report from 1999 [35] and guidelines from ADA [2]. According to ISPAD the diagnosis of diabetes is 
based on BG measurements and/or presence of symptoms [1]:  
1. Fasting plasma glucose (FPG) ≥ 7.0 mmol/l (126 g/dl). Fasting is defined as no caloric intake 
for at least 8 hours.* 
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2. Plasma glucose (p-glu) two hours after oral glucose tolerance test (OGTT) ≥ 11,1mmol/l 
(200g/dl). The test should be performed as described by WHO, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water.* 
3. Symptoms of hyperglycemia and a casual plasma glucose concentration ≥ 11,1mmol/l. Casual 
is defined as any time of day without regard to time since last meal. The classic symptoms of 
hyperglycemia include polyuria, polydipsia, and unexplained weight loss. 
*In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing 
on a different day. 
The clinical diagnosis of T2D in an asymptomatic individual requires at least two abnormal glucose 
values, diagnostic of diabetes on two separate days, or the same criteria as for T1D [1,43].  
In individuals that don‘t fulfil the diagnostic criteria for diabetes, but still present a abnormal picture, 
impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) are measured. IGT and IFG 
are intermediate stages between normal glucose homeostasis and diabetes. IGT is defined as two hour 
post-load glucose between 7.8-11.1mmol/L. IFG is defined as fasting glucose between 5.6-6.9mmol/L. 
IGT and IFG are now referred to as pre-diabetes indicating high risk of developing diabetes. These 
individuals should be tested with an OGTT.  
6.4. Treatment 
The treatment for T1D and insulin dependent T2D is lifelong insulin substitution. Insulin therapy has 
changed dramatically since the first patient was treated in 1922. In the earliest years insulin therapy 
usually consisted of one injection before each meal and one at 1 a.m. When intermediate and long-
acting insulin became available in 1935, most patients moved to one or two injections per day. In the 
1960s it became obvious that those using multiple daily injections (MDI) (≥ four injections per day) 
developed retinal complications less frequently than those on one or two injections a day (9 % vs. 61 
%) [46]. Today, guidelines recommend four or more injections per day. 
In the resent years new insulins and new devices for administration has led to improvement in the care 
of diabetes, but the extent in a clinical long term setting has not been elucidated [47]. Different types 
of insulin are available worldwide; human insulins, porcine and bovine insulins and the newer analogs. 
In children and adolescents no significant improvement in BG control was observed with insulin 
analogs compared to regular insulin, but, however, a reduction in hypoglycaemic episodes has been 
observed among adolescents [48,49]. It has not been demonstrated that human insulins are more 
efficient than porcine and bovine, though the latter has been associated with greater immunogenicity 
[50]. Porcine and bovine insulin may be more economical and more readily available in some parts of 
the world. However, animal species insulins are being withdrawn from the market by the 
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pharmaceutical companies. The major manufacturers are moving towards production of analogs only 
[47], which are 50-100% more expensive than the traditional insulin [51].  
According to ISPAD, children and adolescents should at least have access to adequate amounts of 
regular insulin and intermediate acting, Neutral Protamine Hagedorn (NPH) insulin [47]. In most parts 
of the world regular insulin is still used as an essential component of most daily replacement regimes. 
The advantages with the rapid acting analogs are that they can, when needed, be given immediately 
before meals, or after food intake. Basal insulin analogs are superior to traditional long acting insulins 
and it has also been demonstrated that they produce a more predictable insulin effect with less day to 
day variation compared to NPH insulin [52]. 
Principals of insulin therapy 
The three frequently used regimes are described in ISPAD guidelines: two and three injections daily 
and the basal bolus regime [47]. 
1. Two injections daily with a combination of rapid analogs/regular insulin and intermediate 
acting insulin (before breakfast and the main evening meal). Two thirds of the dose should be 
given in the morning and one third in the evening. One third should be short acting and two 
thirds intermediate acting.  
2. In the regime with three injections daily, insulin is administrated before breakfast; rapid 
analogs/regular insulin and intermediate, before afternoon snack; rapid/regular insulin and 
before bed; intermediate.  
3. The basal bolus regimen require injection of intermediate or basal insulin/long acting analog 
at bedtime or twice daily in addition to injection of rapid analogs/regular insulin before each 
meal. 40-60% should be basal long acting insulin, the rest pre-prandial rapid analogs/regular 
insulin. 30-50% of intermediate acting should be given at night time.  
Daily insulin dosage depends on factors such as age, weight, duration of diabetes, nutritional intake 
and exercise. Optimal dosage should be the dose that best achieves glycemic control. ISPAD 
guidelines suggest [47]: During partial remission phase, sufficient total daily insulin dosage is often 
<0.5 IU/kg/day. Pre-pubertal children (outside partial remission phase) usually require 0.7-1.0 
IU/kg/day. During puberty, requirements may rise to above 1 and even up to 2 IU/kg/day. 
Administration forms 
Currently, the basal bolus-regime is the best way to imitate the physiological insulin profile [47]. 
Continuous subcutaneous insulin infusion (frequently called insulin pump therapy) is often used with 
this regime. Insulin is infused subcutaneously (s.c) at a pre-programmed basal rate and the patients add 
bolus doses to the balance intake of carbohydrates. New modalities such as pumps, pens, subcutaneous 
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indwelling catheters and automatic jet devices are more expensive than the conventional syringes and 
implementation is not possible in many countries [47].  
6.5. Treatment target 
The established treatment target is to maintain the BG concentration as close as possible to normal 
range (3.6-5.8mmol/L). To obtain this, intensive insulin treatment, self-monitoring of BG and regular 
measures of HbA1c is necessary. HbA1c is a form of hemoglobin which is measured primarily to 
identify the average plasma glucose levels for the preceding four to twelve weeks [53] and this serves 
as a marker for long term BG levels but it does not take into account fluctuations, which may play a 
role in development of complications [54].  
ISPAD practical recommendations are based on findings in Diabetes Control and Complications Trial 
(DCCT) [55-57] and United Kingdom Prospective Diabetes Study (UKPDS) [58]. DCCT was a major 
clinical study conducted from 1983-93 and involved 1,441 volunteers with T1D, ages 13 to 39, in 
United States and Canada. UKPDS was a randomized trial involving 5,102 patients with newly 
diagnosed T2D that ran for 20 years (1977 to 1997) in the United Kingdom. DCCT demonstrated that 
intensive diabetes treatment both delays the onset and slows the progression diabetic complications in 
T1D subjects and related lower Hb1Ac values to less complications [56]. The mean HbA1c value after 
three months was 2% lower (7.2% vs. 9.1%) in the intensive treated group compared to the 
conventional group (injections twice daily). In UKPDS each 1% reduction in updated mean HbA1c 
was associated with a 21 %, risk reduction of diabetes related death, 14 % risk reduction for 
myocardial infarction and 37 % risk reduction of microvascular complications.  
ISPAD treatment goals [59] for children with diabetes up to 18 years is HbA1c value less than 7.5% 
and for adults is HbA1c less than 7.0%, both with repeated monitoring every three months. Current 
glycemic targets for patients with diabetes make no distinction as to the type of diabetes. 
6.6. Complications 
Chronic hyperglycemia is associated with damage to small and large vessels, mainly affecting the 
cardiovascular system, the kidneys, the retina and the peripheral nervous system. The Epidemiology of 
Diabetes Interventions and Complications Study (EDIC) was a follow up study of the DCCT, eight 
years after intervention. EDIC [60,61] confirmed the risk reduction for microvascular complications 
and provided evidence that intensive diabetes treatment and improved glycemic control lead to a 
significant risk reduction for macrovascular complications compared to conventional treatment. 
Clinically evident complications are rare in childhood and adolescence T1D, however, abnormalities 
may be present a few years after onset of the disease. On the contrary, clinical presentation of T2D is 
often slow progressing and manifested complications such as dyslipidemia, hypertension and 
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albuminuria may be present at diagnosis and should be assessed after blood glucose control has been 
optimized [43]. In addition, complication testing at diagnosis should include eye examination, liver 
enzymes and control for obstructive sleep apnoea. Risk factors for the development of complications 
are longer duration of diabetes, older age, puberty, smoking, hypertension and family history of 
complications [62,63].   
In general, areas with specialized centres report a declining incidence of complications [63] and areas 
where health care is not optimal hold a greater risk of complications [64]. However, this does not 
undermine the importance of good glycemic control.  
Microvascular complications 
Microvascular complications include retinopathy, nephropathy and neuropathy and they are associated 
with a high degree of morbidity and mortality. 
Diabetic retinopathy 
In developed countries diabetic eye disease is among the leading cause of blindness and it is the fifth 
leading cause of global blindness, affecting an estimated 1.8 billion people [65]. Diabetic retinopathy 
(DR) causes microvascular retinal changes and may lead to visual impairment and blindness. After 20 
years of diabetes nearly all patients with T1D have some degree of DR [66]. Adolescents have a 
higher risk of progression to vision threatening retinopathy compared with adults [62].  
Diabetic nephropathy  
Diabetic nephropathy (DN) is a major cause of morbidity and mortality among young adults with 
T1D. DN is characterized by progressive kidney disease caused by angiopathy of capillaries in the 
kidney glomeruli. It is defined as persistent proteinuria (greater than 500 mg/24 hours) or albuminuria 
(greater than 300 mg/24 hours) [62]. The first clinical sign of progression to DN is microalbuminuria. 
Microalbuminuria is defined in one of three ways [62]: 
 Albumin concentration 30–300 mg/L  
 Albumin excretion rate (AER) between 20 and 200µg/min or AER 30–300 mg/24 hours in 24-
hours urine collections  
 Albumin creatinine ratio (ACR) 2.5–25mg/mmol or 30–300 mg/gm (spot urine) 
Persistent microalbuminuria and DN is associated with decreased glomerular filtration rate (GFR) and 
indicates progression to end stage renal disease (ESRD). ESRD is the prime indication for dialysis and 
kidney transplantation in many Western countries. DN accounts for 25 to 30% of the patients with 
ESRD who require dialysis and it has been estimated that 30 to 40% of patients with IDDM will 
eventually develop ESRD [56,67]. The process can be slowed by intensive treatment as shown in 
EDIC [60]. Only 6.8% of the participants in the previous intensive-treatment group developed 
microalbuminuria and 1.4% developed clinical albuminuria, compared with 15.8% and 9.4% of 
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participants in the previous conventional treated group. The total number of severe kidney events 
(kidney insufficiency) was more than three times greater in the conventional treated group. 
Diabetic neuropathy  
Diabetic neuropathies are a heterogeneous group of disorders which can affect both the somatic and 
autonomic nervous system. Diabetic sensorimotoric polyneuropathy is the most common form and is 
often referred to as ―diabetic neuropathy‖. Neuropathy can cause morbidity with significant impact on 
the quality of life of the person with diabetes, and can result in early death. The major morbidity is 
foot ulceration, which can lead to gangrene and ultimately to limb loss. Diabetic neuropathy is the 
most common form of neuropathy in developed countries and is responsible for 50 to 75% of non-
traumatic amputations [68]. A population survey [69] reported that 30% of IDDM and 36 to 40% of 
non-insulin-dependent diabetes mellitus (NIDDM) patients with diabetes experienced neuropathic 
symptoms. It is expected that diabetic neuropathy is grossly underdiagnosed and undertreated in many 
countries. Management of the disease is complex and the key to success depends, in part, on 
discovering the underlying pathological processes in each particular clinical presentation. There has 
been an increase in the understanding of the pathogenesis of diabetic neuropathies over the last 
decades and new therapies are emerging that hold promise for the treatment [68].  
Macrovascular complications 
Macrovascular complications include heart disease, stroke and peripheral vascular disease (which can 
lead to ulcers, gangrene and amputation). Cardiovascular complications constitute the major cause of 
mortality in patients with T1D and T2D and life expectancy in T2D patients, diagnosed prior to the 
age of 40 years, is reduced by eight years relative to people without diabetes [70]. Epidemiological 
studies have demonstrated that diabetes is an independent risk factor for cardiovascular disease and is 
associated with a two- to fourfold increased risk of coronary heart disease [71,72].  
Type 1 diabetes 
EDIC reported that cardiovascular benefit was observed ten years after intensive treatment [61]; a 42% 
decrease in the cardiovascular event rate and a 15 to 33% reduction in myocardial infarction in T1D 
subjects [57].   
Type 2 diabetes 
It is evident that early intensive glycemic control seems to reduce the risk of cardiovascular event later 
in life. In the last two years several trials among T2D patients [73-75] have investigated if even more 
intensive glycemic control (HbA1c 6.4-6.9% compared to HbA1c 7.0-8.4%) results in a further 
reduction in cardiovascular disease and mortality. Intensive control did not seem to influence the 
outcome in short term (3 to 6 years after) when initiated in those diagnosed many years previously. In 
one study [74], mortality did increase in the intensive treated group and because of the many 
hypoglycaemic episodes, this study was stopped after 3.5 years. It remains unclear if it was the high 
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rate of hypoglycaemic episodes that was the cause of increased mortality. One suggestion was that less 
strict HbA1c goals than 7.0% might be indicated for patients who had extensive co-morbid conditions, 
limited life expectancy, or an increased risk of severe hypoglycemia [76].  
7. PART 2: Diabetes in a global perspective with focus on sub-Saharan 
Africa and Norway. 
In general, data on the impact of diabetes in SSA countries is limited often outdated and full texts are 
not always available electronically. In 2009, the IDF African Region launched its action plan [77] to 
tackle the escalating threat from diabetes. At the same time, ISPAD proclaimed that the new practical 
recommendations had to be applicable for the total diabetes community worldwide [1]. With this in 
mind, it is important to remember that each Sub-Saharan African country is unique. 
Many publications from this region originate from South Africa which is not considered representative 
for the entire region. South Africa is ranked higher (number 110) than most SSA countries on UNs 
Global Human Development Report [78]. The report is based on: life expectancy, Gross Domestic 
Product (GDP) per capita, literacy rate, inequality (disproportionate distribution of income, medical 
services and access to education), the index of gender equality and poverty. Rwanda is ranked number 
152 out of 169 countries and Norway is ranked as number one [78]. It is reasonable to assume that 
countries where it is possible to retrieve data on diabetes care are more developed than the ones where 
data does not exist at all.  
7.1. PART 2A: Diabetes in Sub-Saharan Africa 
7.1.1. Chronic diseases in a global perspective 
The health landscape of SSA is dominated by poverty and a high burden of infectious diseases, 
including HIV/AIDS and malaria. Many African countries now face a double disease burden, with 
increasing numbers of patients with non-communicable diseases such as: hypertension, stroke, 
coronary heart disease and diabetes. Over the last 25 years diabetes has become a major health 
problem in developing countries. While there has been a great improvement in the knowledge, 
epidemiology and management of diabetes in the developed world, there has been little or no 
improvement in SSA.  Professor Jean Claude Mbanya from Cameroon was elected as the first African 
President of IDF from 2009-2012; a sign of new international attention on diabetes in Africa. 
The T2D epidemic seen in the developed world the last years appears to have reached SSA as well. 
Currently, the population of SSA is predominantly rural (34% urban), but by 2025, more than 70% of 
the population will live in the urban areas [79]. T2D is increasing most quickly in developing 
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countries where: rapid uncontrolled urbanization and major changes in lifestyle towards western diets, 
increased food quantity with reduced quality, low levels of exercise, smoking and increased alcohol 
availability as well as increased life expectancy could be driving this epidemic. With the obesity 
problem on one side, it is a well-known phenomenon that malnourishment malnutrition and stunted 
growth in children leads to increased risk of obesity and insulin resistance later in life, predisposing to 
T2D [80,81]. To aggravate the situation further, antiretroviral drugs are widely being used in African 
patients with AIDS, with the metabolic syndrome and T2D as common adverse effects [82].  
It is likely that children with T1D in SSA often go undiagnosed, or if diagnosed do not have access to 
insulin, and die as a result. The outcome from diabetes in some developing countries is similar to 
outcome before the discovery of insulin. In 1980, it was announced that life expectancy of a child with 
newly diagnosed T1D in Tanzania might be as short as one year (20 % died within the first year) [83]. 
Today, the situation appears to have improved in some areas, however, this is not true for all regions. 
IDF Africa published in 2006 an article stating that life expectancy of newly diagnosed children with 
T1D in some countries still could be less than seven months [84]. Unfortunately, studies to confirm or 
disprove this statement are limited.   
7.1.2. Epidemiology in sub-Saharan Africa  
The estimated prevalence of DM in Africa is 1% in rural areas, up to 5% to 7% in urban SSA and 
between 8% and 13% in more developed areas such as South Africa [85-87]. Although the majority of 
patients, 70% to 90%, present with typical T2D, up to 25% are considered to have T1D [88-90]. 
Among the latter group, it is currently estimated that approximately 15% [91] may represent atypical 
presentations of diabetes, especially ketosis-prone atypical diabetes and malnutrition-related diabetes 
mellitus (MRDM). The nature and existence of both these subtypes is still uncertain [82] and there is 
no reliable data. Findings suggest that the characteristics of T1D in people from SSA can differ 
somewhat from typical European populations. One interesting feature of African T1D is that the age of 
onset is about ten years later than elsewhere. In South Africa mean age at presentation was 22-23 years 
African T1D patients [92]. In Tanzania [93] and Ethiopia [94] similar observations were made; the 
peak age at presentation was 15 to 19 years and 20 to 25 years respectively. Half of African American 
patients initially treated with insulin do not have classical T1D [95] and may explain the difficulty in 
classifying and diagnosing some forms of diabetes in Africa. 
Ketosis-prone atypical diabetes mellitus 
Ketosis-prone atypical diabetes mellitus affects people with a T2D phenotype and profile, but the 
initial clinical presentation mimics T1D and presents with severe hyperglycemia and ketosis [43,96]. 
Within days or weeks after initial insulin treatment, long-term remission with or without relapses is 
achieved by low-dose oral hypoglycaemic drugs, lifestyle intervention, or both [96]. 
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Malnutrition-related diabetes mellitus 
MRDM or ―Tropical diabetes‖ was described in the 1960s and 70s and is a rare type of diabetes 
associated with long term malnutrition [97]. It is characterised by insulinopenia, insulin resistance, 
hyperglycemia and failure of the beta-cells in the pancreas, often seen as calcifications. These patients 
are thin, young (below the age of 30 years) and severely hyperglycemic. However, in contrast to T1D, 
these patients do not have ketonuria, do not develop ketosis and they require very high doses of insulin 
for glycemic control [98].  
Prevalence and incidence 
In the IDF Diabetes Atlas report from 2010 (based on DIAMOND) that only four SSA countries 
contributed with data on prevalence and incidence in childhood diabetes [99]. Prevalence of T1D is 
low compared to Western countries (table 1); 0.33 per 1000 in Nigerian schoolchildren [100] and 0.95 
per 1000 in Sudanese schoolchildren [101]. Incidence rates of 10 per 100,000 PYR have been reported 
from Sudan [102] and 1.5 per 100,000 PYR from Tanzania [103]. Kengne et al. [104] refer estimates 
of the total number of patients with T1D and T2D in several SSA countries based on the IDF Diabetes 
Atlas 2000 and the World Bank (table 2). IDT estimate the current overall T2D prevalence on the 
African continent to be 2.4% [105] (compared to 7% in Norway). 
Table 1: Figures on prevalence and incidence of T1D in children and adolescents in Sub-Saharan Africa. *IDDM=Insulin 
Dependent Diabetes Mellitus.PYR= patient-years. 
Country Year Authors Age (years) Prevalence  
(per 1000) 
Incidence  
(per 100 000 PYR) 
Nigeria 1992 Afoke et al. [100] 5-17 0,33  
Sudan 1989 Elamin et al. [101] 7-14 0,95*  
Sudan 1992 Elamin et al. [102] < 15  10,1 
Sudan 1991-1995 Elamin et al.[106] < 15  10,3 
Tanzania 1982-1991 Swai et al.[103] 0-19  1,5 
 
Table 2: Figures on total number of patients diagnosed with type 1 and type 2 diabetes in Sub-Saharan Africa countries 
(based on the IDF Diabetes Atlas 2000 and the World Bank) [104].  
Country Total number of people with diabetes (x1000) 
Type 1 diabetes Type 2 diabetes 
Ethiopia 4.95 268 
Nigeria 12.52 209 
South Africa 57.56 886 
Tanzania 2.47 134.8 
Democratic Republic of Congo 4.8 252.6 
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7.1.3. Mortality in Sub-Saharan Africa 
More than 330,000 people are expected to die from diabetes-related causes in the Africa region, 
accounting for 6% of all deaths in the 20-79 age groups in 2010 [12]. In contrast, diabetes accounts for 
15.7% of deaths in North America [12].  
There is only one longitudinal study on mortality in T1D patients from SSA conducted in South Africa 
from 1982-2002 (mean age 22 years, mean duration 3 years) [89]. Mortality after 20 years was 43% 
(excluding the 40% who were lost to follow-up for unknown reasons). Renal failure as a result of DN 
was the main cause of death (43%) followed by metabolic, particularly hypoglycemia (29%), DKA 
(10%) and infection (10%). Older studies from Sudan [107] and Tanzania [108] reported five year 
mortality rates of 20% (T1D) and 29% (mainly IDDM) respectively. If patients lost to follow-up were 
included, five year mortality rates would reach 50% and 40%. For T2D patients in Tanzania the five 
year mortality rate was 16% [108]. Despite a lack of studies of patients younger than 20 years, there 
are relatively few deaths in this group and this will, therefore, not be affecting the conclusions made. 
Though, misdiagnosis or delayed diagnosis may contribute to false low mortality rate, especially in the 
children less than five years old.  
7.1.4. Complications in Sub-Saharan Africa 
Acute complications 
The acute metabolic complications of DKA, hyperosmolar non-ketotic coma and hypoglycemia all 
commonly occur in Africa and have a worse prognosis than in developed countries. Most children (75-
80%) present with DKA at the time of diagnosis [94,107,109]. Up to 90% of children and adolescents 
with T1D [107,109] reported one or more episodes of DKA over the last six months, other studies 
report a variation from 25-90% [94,107]. Mortality rate of DKA is 10-30% [105] and 41% in 
hyperosmolar non-ketotic coma patients [110]. Severe hypoglycemia with unconsciousness and/or 
convulsions occurs in 25-55% (last six months period) [94,109]. 
Chronic complications 
Populations of African origin have a high prevalence of microvascular complications of diabetes, with 
renal failure (secondary to DN) as the leading cause of death in this group of patients [89]. Most 
studies on diabetic complications in SSA are based on findings in adults and/or do not separate T1D 
and T2D. Current data was difficult to find, the most recent study of complications was from Malawi 
from 2011 [111,112]. It separated T1D and T2D regarding DR but not DN or neuropathy. In a review 
from 2009 [82] references were often more than ten years old.  
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Diabetic retinopathy 
One study from Dar es Salaam, Tanzania [109]  (from 2005-6) involving T1D children and 
adolescents reported that 22.2% had DR (5-18 yrs of age, mean diabetes duration 5 yrs). Two 
longitudinal cohorts included T1D patients, one from South Africa [89] and one from Malawi (T1D 
and T2D) [111]. In South Africa, 59% of T1D subjects developed DR after mean duration 23 years. In 
Malawi, prevalence of DR was 28.1% after mean diabetes duration 6.7 years, of whom 12.5% had 
PDR. In T2D patients with duration longer than five years, prevalence of DR was 23.2% and PDR or 
worse was 3.2%. In those with disease duration longer than 16 years, prevalence of DR was 66.7% 
and proliferative diabetes retinopathy (PDR) and blindness were 14.3%. These findings are similar to 
earlier reports (10-15 years old) where overall retinopathy prevalence in (mainly) adult T2D patients 
varied from 15-56% [88,113-115] depending on the duration of diabetes and glycemic control. 
Diabetic nephropathy 
In a 20 year follow-up cohort from South Africa [89], chronic renal failure (secondary to DN) was 
responsible for up to 50% of all-cause mortality in T1D patients and 1/3 to 1/2 of people in dialysis 
had diabetes. After a mean duration of T1D of 23 years 35 % had [89]. DN was reported in 22% of 
Sudanese patients with IDDM (mean duration 10 years) [116]. In Ethiopian adult IDDM patients 
(older than 18 years) [117] it was found that the prevalence of albuminuria increased from 25% in 
those with a duration less than two years to 80% in those with diabetes duration of ten years or more. 
Microalbuminuria was present in 32% of IDDM patients (mean diabetes duration 6 years) [117]. 
Microalbuminuria was present in 29.3 % of children and adolescents from Tanzania with T1D [109], 
increasing prevalence with older age. Neither of these studies report of pharmaceutical intervention. 
Nephropathy has been reported in 34.7% of Malawian (mainly T2D patients, mean diabetes duration 7 
years) [112]. In Nigeria, nephropathy was reported in 41.1% of T2D patients (mean diabetes duration 
12 years) [118].   
Diabetic neuropathy 
In Sudanese IDDM patients neuropathy was found in 27% (diabetes duration 6 to 10 years) and in 
76% (duration longer than 10 years) [116]. In Ethiopia [119] and South Africa [120] prevalence of 
neuropathy in IDDM patients was respectively 7.9% (mean diabetes duration 15 years) and 42% 
(mean diabetes duration 13.6 years); all data are from 1992-95. In South Africa the prevalence of 
neuropathy was 27.6% after eight years diabetes duration (mainly NIDDM). Neuropathy in newly 
diagnosed Ugandan patients was found in 46.5% of patients (mean age 45 years) [121]; no distinction 
was made between T1D and T2D.  
Diabetes neuropathy was the most common cause (80%) [122] of foot ulcer and the outcome was 
often amputation, 33% in one study [123]. Foot ulcers were found in 15% of all adult diabetic patients 
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[123]. Only 20% of patients undergoing amputation had ischemic gangrene (due to peripheral vascular 
disease) [124]. Due to cultural issues loss of a limb is considered worse than loss of a life in many 
African societies, indicating a complex problem [125]. 
Macrovascular complications 
Macrovascular complications occur mostly in patients with T2D and are becoming more common, 
particularly in the urban setting with a Western lifestyle. In urban adults the prevalence of 
hypertension is 14-16% and obesity varies from 3-44% according to the level of urbanization [126]. 
Ischemic heart disease (IHD) includes angina, coronary artery disease and heart failure. It was until 
recently thought of as rare is SSA but studies have proven otherwise; IHD is present in 5-8% T2D 
African patients [114] and 4.8% of the patients had IHD present at diagnosis of diabetes [104]. 
Cardiomyopathy was reported in 50% of T2D patients [124]. Cerebrovascular disease in a Sudanese 
population was found in 5.5% of patients with IDDM [116]. Diabetes is present in more than one third 
of patients presenting with coronary events and close to 15% of people with stroke have diabetes 
[124].  
7.2. PART 2B: Diabetes in Norway 
7.2.1. Public health in Norway 
Norway maintains a Scandinavian welfare model with universal health-care, subsidized higher 
education and a comprehensive social security system. The health care system is organized into first-
line services, second line services and specialized referral hospitals. The general practitioner provides 
the first line service. In 2004, a new system was implemented where all citizens choose one doctor to 
be their contact person and each doctor has about 1000-2500 patients on his list. The general 
practitioner refers patients to specialist doctors in the second line service and a few is referred to the 
specialized hospitals. There are close to 80 second line hospitals in Norway and 26 of them have a 
pediatrics ward.  
UUH is a second line hospital and the largest hospital in Oslo, the capital of Norway. All children with 
diabetes from the surrounding districts (Oslo, Asker and Bærum) travel to this hospital. The area has a 
total population of 700 000 people. UUH has the biggest department for diabetic children in Norway 
with close to 300 patients at follow-up every year.  
7.2.2. The Norwegian Childhood Diabetes Registry  
The Norwegian Childhood Diabetes Registry (NCDR) was established in 2006. NCDR includes data 
collected prospectively from 1989 and retrospectively from 1973-82. One of the aims is to standardize 
and optimize diabetes care throughout the country. Registration is voluntary and the children (or 
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parents, or both) have to give consent twice; once at diagnosis and once when the patients reach 18 
years.  Annually the NCDR publish a report, addressed mainly to the different hospital pediatric units 
responsible for the diagnostics and follow-up. The hospitals are marked with different codes that only 
the register and the hospital know. In this way hospitals can compare results (HbA1c values, 
epidemiology and insulin administration forms) with other hospitals. In 2009, the register included all 
26 pediatric wards in Norway and included both time of diagnosis and follow-up data. 2314 patients 
(2299 T1D) participated in the annual control, which is estimated to be 92% attendance [25]. Almost 
all children with diabetes in Norway are registered in this registry and in 2009 only nine out of 361 
newly diagnosed patients did not want to register [25]. 
Patient organization 
The Norwegian Diabetes Association is a voluntary, independent patient organization for children and 
adults with diabetes and a member of IDF. It was founded in 1948 with the objective of serving people 
with diabetes and others that has an interest in the subject/disease. Today, the organization is located 
all across Norway with 150 offices and more than 40.000 registered members.  
Diabetes Mellitus in Norway 
Diabetes is a common disease in Norway, out of 4.9 million inhabitants, 375 000 [127] people have 
diabetes. The majority (93%, 350 000 people) have T2D, representing a fourfold increase over the last 
50 years and it is believed that half of these have diabetes without knowing it. Estimated prevalence 
for T2D is 7% and 6 to 7000 people are being diagnosed with T2D every year; mainly people older 
than 40 years [127]. 
The rest (25 000 people) are diagnosed with T1D, giving a prevalence of 0.5%. T1D is often 
diagnosed during childhood and it is the second most common chronic disease (after asthma) in 
children in Norway; total number is 3300 children under 18 years [127]. Approximately 300 children 
in Norway younger than 15 years get diagnosed with T1D every year, which represent a doubled the 
last 30 years.  
7.2.3. Epidemiology of diabetes at Ullevål University Hospital 
In childhood, the distribution between T1D and T2D is quite different from the adult population. T1D 
accounts for 92% of diabetic children younger than 18 years, T2D 2.1% and MODY 6% (2009) [25]. 
Norway has one of the highest incidences of T1D in children and adolescents in the world with 36 per 
100 000PYR (2009) [25]. The incidence has been increasing since the first registration by Westlund 
[128] who estimated the average incidence under the age of 20 years to be 9.8 per 100 000 PYR 
during the period from 1925-1954. Joner et al. [129] found an incidence of 22.4 per 100 000 PYR 
from 1989-1998.  
In 2008, 27 newly diagnosed children with T1D in Norway were diagnosed at UUH. T1D was 
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diagnosed in all age groups with a peak between 13-16 years (figure 1) [25]. The incidence increased 
in 2009 with 48 patients being diagnosed with diabetes. 
 
Figure 1: Age distribution among newly diagnosed children with Type 1 Diabetes at Ullevål University Hospital in 2008. 
7.2.4. Treatment of Type 1 Diabetes at Ullevål University Hospital 
All newly diagnosed children with T1D are admitted to hospital at diagnosis regardless of their 
condition. The average length of stay is eleven days. How long they are hospitalized is dependent on 
their socioeconomic status, how fast they learn how to deal with their diabetes and how comfortable 
they are with the administration procedures. The key point in Norwegian diabetes care is that the 
children with diabetes are the experts on their disease; the doctor is more an advisor. A 
multidisciplinary team is responsible for treatment and follow-up of children with T1D. In this team 
there is a doctor (paediatrician), a diabetes nurse (specialized education for 1.5years), a psychologist, a 
nutritionist and a social worker. The hospital has access to interpreters if the patients do not 
speak/understand Norwegian or English. If interpreters are involved, the duration of hospitalization is 
usually longer because of difficulties with communication.  
The nurses are experienced with diabetes and they are specially trained to be able to educate. Most of 
the education at UUH is individual; group education at diabetes onset is difficult because relatively 
few get diagnosed at the same time. At the hospital, soon after diagnosis, the patient and the family is 
offered an appointment with a social worker and a psychologist. The social worker can help the family 
with the rights and different funding arrangements which they can claim.  
Carbohydrate counting is used systematically. The children and family learn about nutrition and 
healthy food and the effect carbohydrates will have on the BG. The most important thing is that the 
children learn how to count carbohydrates in food and set insulin related to the amount of 
carbohydrates ingested. All children are recommended to eat healthily and to have a diet composed of 
many different kinds of nutrients, without strict restrictions on unhealthy food. 
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Type 1 Diabetes - Insulin therapy 
At UUH 62% of the patients were on insulin pumps in 2009, compared to 52% nationwide [25]. All 
new onsets are offered to start with the pump at diagnosis and 98% of these patients start on a pump. 
The rest of the patients at UUH (38%) are on MDI therapy. The pen is the most common 
administration form (> 99%) with only a few patients using syringes. MDI is most often a combination 
of a long acting analog as Levemir or Lantus and a short acting analog, usually NovoRapid. Patients 
inject at least four injections daily. Nationwide, 65% use the pump in the youngest age group (younger 
than five years old) [25], with the lowest percentage (47.5%) in the oldest age group (15 years or 
older). In puberty the patients have increased need to not be different from peers, which can lead 
difficulties in measuring blood glucose and insulin injections. The insulin pump is especially 
important if the child is very young (less than six years old) because these children often need very 
little insulin, especially in the honeymoon-phase. It is easier to give diluted insulin through a pump.  
Follow-up at Ullevål University Hospital 
Follow-up is once every three months at the OPC and at this appointment the patients see a particular 
doctor each time, who is also the contact person. In between regular follow-ups, the diabetic nurses are 
available on the phone and many ―everyday problems‖ are solved this way. At follow-up the doctor 
and the child discuss together with the parents, the challenges in the insulin/diabetes care. The patients 
are told to write down all BG measurements during the day. The doctor uses this as an instrument in 
changing the insulin dose and to give advice on how to obtain better glycemic control. 
The parents are asked to participate in the treatment and the follow up of the child, at least until the 
child is 16-17 years old. The children attend their appointments without their parents more frequently 
when they get older (16-18 years old). The hospital wants to involve the parents even after the age of 
16 years, so they are encouraged to attend the appointment with their child at least once a year. How 
much the parents participate and are involved, depend on how much responsibility the child takes and 
how much the parents want to be involved. The parents receive 14 days financial support for education 
and supervision in diabetes control at the time of diagnosis. During this period the parents can learn 
how diabetes works how to administrate insulin and learn and how to recognize symptoms of high and 
low blood sugar. Both parents are involved, to avoid one of them becoming ―the expert‖.   
Guidelines of childhood onset Type 1 Diabetes in Norway 
National and UUH guidelines of childhood T1D are based on ISPAD's guidelines [1]. The treatment 
goal for HbA1c is less than 7.5% for children under 18years. In 2008, 17.3% of the patients reached 
their treatment goals. 
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7.2.5. Complications of Type 1 Diabetes in Norway 
There is a screening program for autoimmune diseases and late complications. The screening for 
autoimmune diseases is performed annually for celiac disease and hypo- / hyperthyroidism. In 2009, 
nationwide, 98% of the patients were screened with a blood sample for celiac disease and 98% were 
screened for hypo-/hyperthyroidism with serum thyroid stimulating hormone (TSH) [25].  
Late complications 
Screening for late complications such as retinopathy, nephropathy and neuropathy is performed 
annually from: the age eleven years (in subjects diagnosed with diabetes for more than two years) or 
from age nine years (in subjects diagnosed with diabetes for more than five years).  
Retinopathy 
Retinopathy is tested by an ophthalmologist with fundal photography or ophthalmoscope. At UUH in 
2009, 0.2% of the diabetic patients younger than 18 years had DR at follow-up in 2009. In a 
nationwide cohort of patients diagnoses with childhood diabetes from 1973-82 [66] DR was reported 
in 89.1% of T1D patients (mean diabetes duration of 24 years), of whom 31% had PDR. In T2D adult 
subjects 15 % had DR after mean diabetes duration of six years [130].  
Nephropathy 
Nephropathy screening involves a urine sample. At UUH in 2009, microalbuminuria 
(albumin/creatinine ratio > 2.5 mg or albumin excretion rate > 20µg/min) was found in11%, persistent 
microalbuminuria was found in 0.6% and proteinuria in 0.4% of the diabetic patients under 18years. 
After mean diabetes duration of 24 years, overt nephropathy was found in 7.8% of T1D patients 
diagnosed at 0-14 years in 1973-82. Persistent microalbuminuria was found in 14.9% of the subjects 
[131]. In this study 43% of the subjects with microalbuminuria were treated with angiotensin 
converting-enzyme inhibitors or angiotensin receptor II blockers, to avoid progression from 
microalbuminuria to overt nephropathy. Microalbuminuria is also associated with increased 
cardiovascular mortality and morbidity. After six years mean diabetes duration of adult T2D, 16 % 
developed DN [130]. 
7.2.6. Mortality of Type 1 Diabetes in Norway 
Childhood T1D carries a fourfold increased mortality risk when compared with the background 
population in Norway [132]. Overall mortality rate was 2.2 per 1,000 PYR in subjects diagnosed with 
childhood diabetes [132]. Survival rate was 98.9% at ten years and 94.6% at 25 years [132]. The main 
cause of death in individuals older than 30 years of age was cardiovascular disease. The most common 
cause in young patients younger than 30 years was acute metabolic complications [132].  Violent 
deaths, suicide and intoxication were responsible for 29% of the total deaths.  
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7.2.7. Quality of life in children with diabetes in Norway 
Patients with chronic diseases will be affected in their daily life. However, at UUH it is emphasized 
that the children are not diabetics; they are children with diabetes. Children with diabetes have to 
organize and structure their day differently than non-diabetic children. However, with good metabolic 
control, diabetes should have minimal affect on everyday life situations. 
T1D can have severe consequences if insulin dosage is miscalculated and many parents risk becoming 
overprotective towards their children. Sometimes children with diabetes develop anxiety and 
avoidance of activities that they would have participated in if they did not have diabetes. To avoid 
situations like these, the patient receives assistance (information and education) in relation to school, 
hobbies and sports. Soon after diagnosis, the nurses offer to go out to schools and kindergartens and 
educate teachers/caretakers about diabetes. From the third grade the nurses go in the classes and teach 
the pupils about diabetes if a child in the class has this disease. The teachers learn about: diabetes in 
general, insulin and how this works and about hypoglycemia and what to do if this happens. They are 
also taught how to roughly count carbohydrates and how to find the right insulin bolus in relation to 
food, this way they can observe the children when he/she set their insulin and see if the insulin dose 
they are about to give seems reasonable. The teachers are allowed to give insulin if the child uses a 
pen or a pump. Most of the children in school are on pumps, the school nurse are very little involved 
in daily diabetes care Usually one school nurse works at four to five different schools and does not 
have the time to proper follow-up.  
The parents are often involved in deciding daily insulin dosage; either they make a form with insulin 
boluses in relation to BG, or they are available on the phone as many children have cell phones and 
can call their parents before a meal to get help. The parents are responsible for teaching activity 
leaders/sport coaches, especially how to handle hypoglycemia (the hospital has special information 
brochures). If there is an interest the leaders/coaches/teachers can visit the hospital and get education 
from a diabetes nurse, or they can get some information about the disease over the phone.  
The hospital arranges re-education for the patients. Once a year they have a group for girls about nine 
to ten years old and all children get re-educated at the age of twelve years.  The aim for these meetings 
is that the patients can meet other people in the same situation and learn that they are not the only ones 
with diabetes. The parents also discuss problems and experiences around having a child with diabetes. 
In Norway, they are conducting research on the quality of life among children with diabetes. In 2009, 
a big study on the quality of life was initiated; this project will keep on going in 2010. 
 Lene Sleire  
Page 27 of 65 
   
8. PART 3: Public health and diabetes in Rwanda – a partly personal 
observational study 
8.1. Public health in Rwanda 
The structure of the health care system in Rwanda is organized into 34 district hospitals and five 
reference hospitals; two university hospitals, one military hospital, one psychiatric hospital and a 
hospital whose mission is to provide specialized services not available in the other reference hospitals 
in order to limit the cost of evacuations outside the country [133]. Local health care centres provide 
first line service. They are run by nurses with a license to prescribe medication such as antibiotics, 
anti-malaria medication, antipyretics, anti-inflammatory, analgesics and proton pump inhibitors. The 
health care centres refer patients to the first line hospitals. Patients who cannot receive proper 
treatment here have to be referred to a second line hospital. Communicable diseases constitute 90% of 
chief complaints in health care facilities [133] 
The share of the budget allocated to the health sector increased from 3.2% in 1996 to 12% in 2009 
[133], which is still lower than the 15% target as other nearby countries with same level of economy 
achieve. However, 4/5 of the budget (58.6 billion RwF~7 billion EUR) is devoted to the offer of 
services and only less than one-fifth to administration. 75% of the doctors were in the city of Kigali, 
where approximately 15% to 20% of the entire population lives. 75% of the population lives within 
less than five kilometer from a health care facility.  
WHO estimated that 30,000 people had diabetes in Rwanda in 2000 and predicted that by 2030 the 
prevalence would reach 77,000 people [134]. There has neither been established an official diabetes 
registry in Rwanda of childhood diabetes nor of diabetes in general. However, Association Rwandaise 
des Diabétiques is a Rwandan patient organization. One of their partners, Fraternité, publish free of 
charge leaflets providing basic information about diabetes to hospitals, dispensaries, and health care 
centres. Though tiny in comparison, such awareness-raising initiatives are effective in saving the lives.  
Due to lack of data, this case study provides some facts about childhood diabetes care in Rwanda.  
8.2. Case study 
Data was collected retrospectively for all diabetic children diagnosed at or before the age of 15 years, 
who were admitted to the Department of Pediatrics at UTHB in Rwanda from October 2008 to 
October 2010. Patients older than 15 years were treated at the ward for internal medicine. Patients 
were referred from district hospitals in the Butare region or from community health centres via district 
hospitals. Diabetic children in Rwanda were routinely admitted to reference hospitals at the time of 
diagnosis for initiation of insulin therapy and stabilization of metabolic control. After discharge from 
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hospital, they were usually seen at the OPC once every month if their metabolic condition was stable 
and satisfactory. They are encouraged to seek medical help if they became sick due to diabetes or from 
other reasons.  
Diagnosis of DM is based on elevated plasma glucose (p-glu > 200 mg/ml or >11,1mmol/l) combined 
with clinical manifestations of diabetes; polyuria, blurring of vision, polydipsia, weightloss, glucosuria 
and ketonuria. Ketoacidosis is diagnosed on clinical grounds in acutely ill patients with impaired 
consciousness, dehydration, acidotic breathing, hyperglycemia and glucose in the urine and on one 
occasion ketones in urine. Bicarbonate and pH is not measured. None of the patients died while being 
admitted to hospital. The BG is measured in g/dL from a venous blood sample, analyzed at the 
hospital laboratory, however, on rare occasions the nurses use a glucometer. The value in g/dl is 
divided with a factor 18.01 to get the value in mmol/L. 
The patients with a persistently poor metabolic condition, other severe illnesses and those presenting 
with complications are re-admitted to hospital. The Department of Pediatrics keep careful register of 
all admitted patients including patient name, date of birth, date of admittance/discharge and diagnosis 
at discharge. Clinical records are stored in the archives and it is due to this method of registration only 
possible to retrieve those who had diabetes as diagnosis at discharge.  
In the observational period at the ward for internal medicine, two patients with severe foot ulcers as a 
complication of T2D were admitted, both around 30 to 35years of age. 
8.3. University Teaching Hospital of Butare 
UTHB have 7060 inpatients per year and 30 915 outpatients per year (2010) (personal comm. hospital 
administration). The hospital has a ward for internal medicine, surgery, gynaecology and obstetrics 
and paediatrics. 1,8mill people live in the area of UTHB [135]. According to the National Commission 
of Poverty Reduction, the three provinces covered by UTHB are the poorest of the territory, though 
the general standard of Rwandan health care is poor, for example, there are only two dialysis machines 
(at UTHB and in Kigali) and only one CT scan in the country (Kigali). To get dialysis one has to write 
a personal letter to the president, who is the only one who can give permission. There was an 
electrocardiogram (ECG) machine at the hospital I worked in, though; during the observation period 
of seven weeks there was no ECG-paper.  
Specialist training has been challenging since there are relatively few specialists in Rwanda. It is 
common that specialists from surrounding countries (or from European countries) come to Rwanda for 
a shorter or longer period of time to teach graduates. 
The Paediatrics ward 
The pediatrics ward has two rooms with 13 and 14 beds in each room, 27 beds in total. The ward is 
rarely overloaded. Three pediatric specialists, six post graduate doctors, two generalist doctors and 
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four internship doctors work at the ward. The interns have the main practical responsibility, but the 
senior doctor can give advice. Once a week all the doctors, interns, medical students and nurses do a 
ward round lead by one of the specialists, Professor Iraka. The interns rotated having the evening and 
night shifts together with one post graduate doctor. Five nurses worked at daytime, two during the 
evening/night shift. The nurses speak mainly French, the doctors speak mainly English and the 
patients speak mainly Kinyarwanda (local language). The majority of nurses and doctors speak 
Kinyarwanda, except a few foreign doctors. This language conflict is a result of the shift from French 
to English as official language in 2007. Nurses educated before 2007 have, therefore poor, knowledge 
of English. Professor Iraka is one of three specialists at the Pediatric ward at UTHB. He is a dedicated 
professor and highly acknowledged by colleagues and medical students. He is originally from Uganda, 
where he took his medical degree but has been working for the past three years in Rwanda at UTHB.  
8.4. Guidelines diabetes care at the University Teaching Hospital of Butare 
There is no specific protocol for diabetes care at UTHB (personal communication professor Iraka). 
The doctor is in charge of everything concerning the treatment; fluids, electrolytes and insulin, both in 
the acute phase and during follow up. The nurses inject the insulin and draw blood for testing. The 
nurses do not make adjustments. Relatively few day to day symptoms are noted in the patient records. 
For acute management of DKA, the guidelines used at UTHB are described in the book ―Pediatric 
Emergencies‖, by Francois DeVilliers (personal communication professor Iraka). 
8.5. Results 
Epidemiology 
The hospital records of eight children (eight records) with T1D were found out of eleven registered 
patients. Total number of registered files was 15 due to several re-hospitalizations. All patients 
fulfilled ISPAD and WHO criteria for diagnosis of T1D in children [1,35]. In the observation period 
from November 2008 to October 2010, four new onset T1D cases were registered (table 3). All four 
patients were diagnosed in 2010, none in 2009. The other four were due to re-hospitalization 
(diagnosed T1D 3-5 years earlier). All patients were prone to ketoacidosis and required insulin for 
survival. In this group, there were four girls and four boys giving a male: female ratio of 1:1. The 
mean age at diagnosis was 10.2 years; 10.9 years for female, and 9.5 years for male. A history of 
known T1D in a close relative (the mother) was reported by one (12.5%) patients. Local standards on 
growth and pubertal development are unknown but many of the children (both new onset and re-
hospitalisation) were reported to be under the third percentile.  
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Table 3: Comparison between epidemiology in childhood diabetes care in Rwanda, represented by University Teaching 
Hospital of Butare (UTHB) and Norway, represented by Ullevål University Hospital (UUH) in 2009. UTHB classify children 
under 15years, while UUH classify children under 18 years. T1D=Type 1 Diabetes. T2D=Type 2 Diabetes 
 University Teaching 
Hospital of Butare (2009) 
Ullevål University Hospital 
(2009) 
Total diabetic patients hospitalized 3 - 
New onset diabetes patients 0 (4 in 2010) 48 
Newly diagnosed T1D patients 0 (4 in 2010) 44 
Newly diagnosed T2D patients 0 1  
Newly diagnosed MODY patients 0 3  
Age at onset (years) 10.2 (3.5-14) 8.1 (0.4-14.9) 
Duration of first time hospitalization 
(days) 
33 11 
 
One patient became diabetic at 3.5 years and the oldest at the age of 14 years. Three patients were 
diagnosed between ages 4-11.5 years (pre-puberty) and four patients between 11.5-15 years (puberty). 
Duration of symptoms before diagnosis ranged from four days to two months with a median of 20 
days. Mean BG at hospitalization was 21,7mmol/L. Mean BG at discharge was 12,0mmol/L. The 
highest measured BG for all patients was 35.5mmol/L and the lowest was 0.6mmol/L. All patients had 
huge swinging values from day to day, but also during the day. Mean duration of hospitalization for 
first time hospitalizations was 33 days, the shortest was 25 days and the longest stay was 37days. The 
mean duration of re-hospitalization was 19 days. 
Table 4: Diabetic ketoacidosis in children with Type 1 Diabetes in Rwanda represented by University Teaching Hospital of 
Butare and in Norway, represented by the Norwegian Childhood Diabetes Registry in 2009 compared to ISPAD Guidelines. 
Rwanda classify children under 15years, while Norway classify children under 18 years.  
 University 
Teaching Hospital 
of Butare
 
Norwegian 
Childhood Diabetes 
Registry 
ISPAD Practical Guidelines 2010 
DKA diagnostic 
criteria 
Clinical symptoms  Clinical symptoms 
and biochemical 
criteria 
Clinical symptoms and biochemical criteria: 
Hyperglycemia (BG >11 mmol/L [≈200 
mg/dL]), venous pH <7.3 or bicarbonate 
<15 mmol/L, ketonemia and ketonuria. 
DKA at onset (%) 100 25 As few as possible 
Patients re-
hospitalized with 
DKA (%) 
Unknown  5 As few as possible 
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All first time hospitalized children (100 %) and two (50%) of the re-hospitalized patients presented 
with DKA (table 4). Symptoms and clinical findings for the re-hospitalized patients varied greatly 
from lung crepitations, failure to thrive, hepatomegaly, jaundice, dark urine, edema, caugh, systolic 
murmur, gallop rhythm, raised jugular vein pressure (JVP), acites, subcostal retractions, and epileptic 
seizure. First time hospitalized patients showed little signs of other organic or chronic disease (fig. 2).  
 
 
Figure 2: Reported symptoms at admission to hospital in the eight case reports. One patient can have many symptoms.JVP= 
jugular vein pressure. 
Mortality 
The following section is based on personal communication professor Iraka. Surveys on mortality rate 
due to diabetes have not been performed in Rwanda. From experience, life expectancy for people with 
diabetes is 30 to 35 years old, many of them die as teenagers as well. It is difficult to say how many 
children die from DKA at home and how many children die from DKA at the hospital; in general it is 
reasonable to assume that most kids die from DKA at the district/university hospital, not at home. This 
makes it difficult to estimate mortality rate. If the parents recognize it as DKA or an acute illness that 
needs hospitalization, not many patients die before reaching the hospital.  
0 50 100
Polyuria
Polydipsia
Frequent drinking
Weight loss
Asthenia, fatigue
Abdominal pain, vomiting
Dehydration/dry skin
Hyperventilation/Kussmaul respiration
Ketone breath
Somnolent
Coma/unconscious
Fever (>37,5)
Urine ketones
Lung crepitations
Hepatomegaly
Jaundice
Dark urine
Edema (peripheral or facial)
Cough
Systolic murmur
Gallop rhythm
Raised JVP
Acites
Subcostal retractions
Epileptic seizure
Percentage
Reported symptoms in new onset childhood diabetes and in rehospitalized 
patients
Re-hospitalized 
patients (%):
New onset 
childhood 
diabetes (%)
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Incidence 
According to experience there has been an increasing rate of DM over the last three years at UTHB. 
UTHB drain 1.8 mill people, half of these (770 000) are younger than 15 years. Diabetes is still an 
unknown disease, but in general people are getting better to seek professional medical care and there is 
greater awareness on health (personal communication professor Iraka). Based on four cases of new 
onset T1D in 2008-10, estimated mean annual incidence would be 0.3 per 100 000 PYR (table 5), 
which is among the lowest incidences in the world.  
Table 5: Incidence rate in childhood diabetes in Rwanda (estimate based on this study, mean annual incidence 2008-10) and 
in Norway [25] in 2009.  
 Rwanda (2008-10) Norway (2009) 
Incidence rate (per 100 000 patient-years) 0.3 36 
 
Treatment 
All of the patients were treated with regular insulin and the most common regime was the combination 
of Actarapid (rapid acting regular insulin) and Ultratard (long acting regular insulin) (87.5%) (table 6). 
One patient (12.5%) was treated with intermediate acting insulin combined with rapid acting. All 
patients (100%) were given two injections per day (figure 3); 2/3 of total dose was given before 
breakfast (2/3 long acting, 1/3 rapid) and 1/3 of total dose before dinner (2/3 long acting, 1/3 rapid). 
Intermediate acting insulin was preferred over long acting but seldom available at the pharmacy. The 
ideal regime consisted of three injections per day but it was observed poorer compliance and outcome 
and thus, injections twice daily was re-established (personal communication JWO Iraka). All patients 
used syringes to inject insulin. 
 
Figure 3: Insulin treatment regime in Rwanda University Teaching Hospital of Butare and in Norway at Ullevål University 
Hospital in 2009. 
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Table 6: Insulin treatment in children with Type 1 Diabetes at University Teaching Hospital of Butare (Rwanda) at Ullevål 
University Hospital (Norway) in 2009 compared to ISPAD Guidelines. ISPAD=International Society for Pediatric and 
Adolescent Diabetes.  
 University 
Teaching 
Hospital of 
Butare 
Ullevål 
University 
Hospital 
ISPAD Practical 
Guidelines 2010 
Ultralente (long-acting) + 
ActaRapid (regular soluble) (%) 
87.5 0  
Intermediate acting insulin 
should be available to all 
patients. Analogs are 
preferred over regular and 
traditional insulin. 
 
Monotard (intermediate acting) 
+ ActaRapid (regular/soluble) 
(%) 
12.5 0 
Levemir/Lantus + NovoRapid 
(analogs) (%) 
0 100 
Self adjusting the dose (%) 0 100 Recommended 
 
The mean number of measured BG value (in hospital) was 1.4 times per day. It is difficult to avoid 
swinging values with only one or two BG measurements a day, especially in a new environment 
(hospital) where other factors could influence BG such as abnormal food intake, low level of physical 
activity and concurrent infections. Home blood glucose monitoring was not used and simple urine 
glucose testing was not performed regularly. The price for a glucometer was 5000RwF (6 EUR) 
(including one month supply of strips), equal to 5-6 days of work. Even with the means to buy a 
glucometer it was experienced difficult to educate patients to be qualified to make dose adjustments. 
Thus, dose adjustments were rarely performed by the patients according to daily activities or other 
illnesses. In the first weeks after diagnosis, the average daily dose of insulin required to achieve 
reasonable metabolic control was 0.6-1,3IU/kg/d. At discharge the insulin dose varied little, from 0.9 
IU/kg/d to 1.1 IU/kg/d. During hospitalization, it was many times reported that insulin was not given. 
Sometimes it was reported that insulin was not given because it was not available but most of the 
times the reason was not recorded. It was not possible to measure HbA1c at UTHB. In 2005, none of 
the medical centres in Rwanda were able to monitor HbA1c [51]. 
Acute treatment of ketoacidosis 
Fluid replacement was given first; 500ml first hour, then at a slower rate. Insulin used for intravenous 
administration and sliding scale was rapid acting regular insulin. All patients started on hourly insulin 
infusions, switched to sliding scale and then to s.c injections. The mean time until introducing s.c 
injections was 3.6 days (range 1-8 days). First time hospitalized patients spent twice as many days 
before getting on s.c insulin as the re-hospitalized patients; 4.8 days (2-8) compared to two days (1-4). 
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Potassium was measured in three out of four (75%) of first time hospitalized patients and ordered in 
one patient (no records of it being measured). Hypokalemia was reported in two of the patients 
(2.1mmol/l, 2.3mmol/l, reference value: 3.5-5.1mmol/L).  Potassium replacement (KCl) was given to 
one of these patients, not available to give to the other. This patient received KCl 20mmol/l/2h at the 
second day and 20mmol/l/12hour at the third day. The fourth day the patient had an episode of 
hypotension with cold extremities. There was not performed a control potassium after receiving the 
fist bag of KCl. Potassium was neither measured in the re-hospitalized patients. 
Table 7: Diagnostic criteria for diabetes, treatment goals and follow-up at University Teaching Hospital of Butare (Rwanda) 
and at Ullevål University Hospital (Norway) in 2009, compared to ISPAD Guidelines. Rwanda classify children under 
15years, while Norway classify children under 18 years. ISPAD=International Society for Pediatric and Adolescent Diabetes. 
HbA1c= Hemoglobin A 1 c. DKA=Diabetic ketoacidosis.  
 University 
Teaching 
Hospital of 
Butare 
Ullevål 
University 
Hospital 
ISPAD Practical Guidelines 2010 
Diagnostic criteria Casual plasma 
glucose >11.1 
mmol/l and 
symptoms 
ISPAD 
Guidelines 
One criteria out of three: 
1. Fasting plasma glucose ≥7.0 and 
symptoms 
2. Plasma glucose 2h after oral glucose 
tolerance test >11.1mmol/l  
3. Casual plasma glucose >11.1mmol/l 
Multidisciplinary team  Doctor ISPAD 
Guidelines 
Doctor, diabetic nurse, nutritionist, social 
worker, psychologist. 
HbA1c Not performed Every 3. 
Months 
Every 3. Months 
Treatment goal Not classified HbA1c < 7.5% HbA1c < 7.5 for children up to 18 years. 
Follow-up frequency Every month Every 3.Months Every 3. Months 
Children at follow-up Unknown 270  
Follow-up attendance 
(%) 
Unknown 98 100 
Follow-up and complications 
The nurses taught the children how to do the poking. The patients went home with a follow-up every 
month at the OPC to get a new insulin prescription and they got insulin from the hospital pharmacy. 
This was a way of guaranteeing that the patients came back for follow-up. Most of them came back 
every month. In this region it is rare to have a refrigerator at home, thus, the usual way to store insulin 
is to bury it in the soil. Waiting time for an OPC consultation was often more than six hours and the  
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travel could take up to five hours each way (often by foot). One parent usually followed the child. It 
was uncertain how many patients who were lost to follow-up (personal communication JWO Iraka). 
No information given to the families about the effect of the disease or quality of life could be detected 
from the records. One patient (12.5 %) was reported to have had discontinued his schooling because of 
the disease. There were no endocrinologists, specialized diabetic nurses, psychologists, nutritionists or 
social worker at the hospital (table 7).  
Table 8: Complication screening at University Teaching Hospital of Butare (Rwanda) and at Ullevål University Hospital 
(Norway) in 2009, compared to ISPAD Guidelines. Rwanda classify children under 15 years, while Norway classify children 
under 18 years. ISPAD=International Society for Pediatric and Adolescent Diabetes. TSH=Thyroid stimulating hormone. 
 
During hospitalization symptoms of severe hypoglycemia were reported twice but not classified as 
hypoglycemia in the files (measured BG 0.6 and 1.9mmol/L); decreased consciousness, no speech, 
and agitation. Hypoglycemia occurred usually as a result of low food intake (due to not having food or 
not wanting to eat) and after a too high dose of insulin. Hypoglycemia was reported once after a 
patient developed a fever. Long-term complications were not screened for or recorded (table 8 and 9). 
 
 
 University 
Teaching Hospital 
of Butare 
Ullevål 
University 
Hospital 
ISPAD Practical Guidelines 2009 
Complication 
screening 
Not performed 98% of patients 
screened 
annually for 
retinopathy and 
nephropathy 
Retinopathy: fundal photography or 
mydriatic ophthalmoscopy. 
Nephropathy: urinary albumin/creatinine 
ratio or first morning albumin 
concentration. Annually screening, 
commence 2 years after onset for 
pubertal-onset T1D and after 5 years or 
age 11, whichever is earlier for pre-
pubertal onset.  
Neuropathy: history and phys. 
examination. Unclear when to commence. 
Macrovascular disease: lipid profile every 
5 years, blood pressure annually. After 
age 12 years. 
Co-
morbidity 
screening 
Not performed Screened TSH. 
98% of patients 
was screened for  
celiac and hypo- / 
hyperthyroidism  
Annually for autoimmune diseases; Celiac 
disease (blood test), hypo- / 
hyperthyroidism (TSH). Every third year 
screening for Addison‘s disease.  
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Table 9: Figures on prevalence of diabetic complications in children with Type 1 Diabetes in Rwanda and in Norway in 
2009. In Rwanda children are under 15 years, in Norway children are under 18 years). The Norwegian Childhood Diabetes 
Registry provides data for Norway and UTHB provides data for Rwanda. UTHB= University Teaching Hospital of Butare. 
 Rwanda (UTHB) Norway (Norwegian Childhood 
Diabetes Registry) 
Retinopathy <18years Unknown 0.2% 
Persistent microalbuminuria <18years Unknown 0.6% 
Albumin/creatinine ratio > 2,5mg or 
albumin excretion rate >20µg/min 
<18years 
Unknown 11% 
Proteinuria <18years Unknown 0.4% 
Comparison of diabetic complications in Sub-Saharan Africa and Norway 
Prevalence of DR is increasing along with longer duration of diabetes. Few longitudinal studies were 
performed. South Africa [89] reports significantly lower prevalence (59 %) of DR in T1D subjects 
compared to Norway (89.1%) [66] , mean duration respectively 24 and 23 years. In the South African 
study close to 50 % of the subjects were lost to follow-up and only 17 of the originally 88 survived to 
participate in the 20 year follow-up. Almost all original subjects in the Norwegian study participated 
in the follow-up. It is reasonable that many of the lost subjects had DR and true prevalence is probably 
higher. Among Tanzanian schoolchildren DR was higher in the pre-pubertal (4-11.5years) and post-
pubertal (15.5-18years) group than the puberty age group (11.5-15.5years), indicating that some of the 
children died before puberty or were lost to follow-up for other reasons [109].  
 
Figure 4: Comparison between Sub-Saharan countries and Norway and the development of diabetic retinopathy after a given 
duration of diabetes mellitus. T1D= Type 1 diabetes. T2D= Type 2 diabetes.  
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South Africa reports a lower rate of DN compared to surrounding countries (same confounder as 
mentioned above). Complication rate increases with longer duration. As the complication rate in SSA 
countries is higher at an earlier point than Norwegian subjects, it is evident that this difference will 
increase with longer duration. Microalbuminuria was found in twice as many Tanzanian and Ethiopian 
T1D subjects after five years as after 24 years duration of T1D in Norway. The rate reported from 
Ethiopia after ten years duration of IDDM is significant higher compared to the other countries.  
 
Figure 5: Comparison between Sub-Saharan countries and Norway and the development of diabetic nephropathy after a 
given duration of diabetes mellitus. Nephropathy is defined as having persistent proteinuria or albuminuria. 
Microalbuminuria is plotted for Tanzania and Ethiopia. IDDM= insulin-dependent diabetes mellitus. T1D= Type 1 diabetes. 
T2D= Type 2 diabetes.  
9. PART 4: Comparison between Rwanda and Norway 
Rwanda and Norway are two very different countries in different parts of the world. Rwanda is a small 
Sub-Saharan African mountain country with one of the highest population density in Africa. In 
comparison, Norway is 15 times bigger in size and has only 4.9 million inhabitants [136]. Table 10 list 
a few differences between Rwanda and Norway. Despite great economic growth and relatively stable 
political conditions in Rwanda since the Genocide in 1994, it is still considered a developing country. 
Life expectancy in Rwanda is 58 years (increasing rapidly from 39.9 years in 2003) [137] compared to 
80.2years in Norway [137]. Norway is a democratic, constitutional monarchy located in the north of 
Europe as a part of the Scandinavian countries (Norway, Sweden and Denmark).  
Norway is divided into 19 regional units and into 435 local municipalities. In the 1970s the discovery 
of the oil on Norwegian continental shelf transformed the country from a below median wealthy 
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country in Western standard to one of the richest countries in the world. Along with economic growth 
the standards of living became better and public health improved.  
Table 10: Differences between Rwanda and Norway. 
 Rwanda Norway 
Population (mill.) [136] 10.7 4.9 
Population density (inhabitants per k m
2
) [136] 420  16 
Rural population [136]  80 %  25 % 
Inhabitants per doctor 33 000 [133] 229 [138] 
GDP ($ per capita) [136] 88.6 mill 535 
Life expectancy [137] 58  80.2 
 
9.1. The Rwandan Genocide  
In the months of the Genocide in 1994 Rwanda received great international publicity. Genocide 
affected the entire population, and marked the Rwandan people for a long time after. Within three 
months in 1994 over one million Rwandan people got killed; the majority was brutally murdered with 
machetes. The background for the genocide was the longstanding conflict between the two main tribes 
in Rwanda; the Hutus (85% of the population) and the Tutsis (12%). A lot was blamed on colonialism, 
especially the Belgians, who initially introduced so-called racial cards in the 1920s. The racial cards 
caused the development of an unfair political and educational favouritism of the Tutsis at first and 
later (in the 80-90s) the Hutus. In 1994, the conflict culminated with a Hutu president being killed. 
The Hutus blamed the Tutsis and the killing started. What made this genocide even more special was 
that this happened in a society were Hutus and Tutsis traditionally lived peacefully side by side and 
suddenly neighbours murdered neighbours and husbands murdered their wives. During the genocide 
many women got raped by HIV positive men with the result of many HIV positive children.  
The HIV/AIDS rate is currently declining due to successful anti HIV/AIDS campaigns but still the 
prevalence is around 3% [133]. Another challenge is that more than 600 000 children are orphans 
[133]. Many of them live together with other relatives, but for some all relatives died during Genocide, 
from HIV/AIDS or from other diseases. In 2009, there were 7 000 street kids in Rwanda. There are 
various reasons that a child becomes a street kid; some seek a better life in the bigger cities, some have 
lost their parents, others can‘t afford to go to school and end up on the street instead. These children 
are often rejected from their families, neglected by society, very few go to school and the crime rate is 
high. If diabetes was added to this picture, the expected outcome is poor. 
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9.2. Child mortality rate 
Child mortality rate (CMR) is an indicator of the quality of general health and health care system in a 
country. Developing countries have in general a higher CMR than developed countries.  In SSA one in 
eight children (12%) die before their fifth birthday. The United Children‘s Fund (UNICEF) estimated 
that CMR in children younger than five years in Rwanda was 200/1000 (20%) of live births in 2009. 
However, there were huge disparities between rich and poor households in developing countries. The 
high CMR in Rwanda stands in great contrast to the low CMR in Norway at 4/1000 (0.4%).  
9.3. Discussion 
Diabetes care in Norway and in Rwanda differs greatly and it is not possible to oversee the enormous 
difference in economic means. With this said, physicians and nurses in Rwanda deserves credibility 
for the effort and work despite lack of technological equipment, which reminds us about the 
importance of the good clinician. It is worth noticing that the total number of diabetic children seen by 
a Norwegian doctor is much higher (48 newly diagnosed each year at UUH compared to four patients 
the past two years at UTHB). Naturally, a physician that treats a large quantity of diabetic children 
will improve his clinical experience and obtain a better outcome for the patients. The DERI study 
confirmed this statement comparing clinics in Europe [26]. 
Epidemiology  
The clinical presentation of childhood diabetes observed in this study of eight case reports from 
Rwanda is in accordance with classical symptoms of T1D [1]. None of the patients were obese and 
none of them showed any of the known features of T2D or atypical ketosis-prone diabetes. An 
interesting finding was that all newly diagnosed children received relatively high doses of insulin (0.9-
1.1IU/kg/day). Insulin requirements are known to be less than 0.5IU in the remission phase and 0.7-
1.0IU/kg/day outside partial remission phase and even up to 2IU/kg/day in puberty. No such 
distinction was found here but the doses are fairly equal to ISPAD recommendations. The high dose of 
insulin required at diagnosis combined with growth under the third percentile for some of them could 
indicate that these children had a different subtype of diabetes such as MRDM. As all children were 
prone to ketosis and DKA and otherwise presented a classical picture of T1D, it is unlikely these 
children had MRDM, though this need to be further investigated. 
It is likely that there is an underestimation of diabetes in Rwanda, partly due to misdiagnosis (children 
presenting with diabetic coma are likely to be diagnosed with cerebral malaria or meningitis) [139] 
and partly because of the high CMR. A natural consequence of high CMR is that it becomes fairly 
common to lose a child in Rwanda; this is considered rare in Norway.  
The age distribution of the patients demonstrated a peak around puberty (12-14 years), similar to 
findings in the DIAMOND study [14] and at UUH in Norway (peak between 13-16 years). Several 
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countries [18-20] reported that diabetes was frequently diagnosed in the younger age groups and South 
Africa, Tanzania and Ethiopia [92-94] reported a peak around 20 years. In this study the peak age of 
diagnosis in Rwandan children was 10.2 years, compared to 8.1 at UUH in Norway. No conclusions to 
support or disprove these trends can be made because: the material is limited, CMR is high 
(underestimation in the youngest age group) and because this study does not involve children older 
than 14 years.  
T2D was observed among older patients and it is reasonable to believe that a distinction between T1D 
and T2D was done. This study involved very few individuals, therefore, any estimation of prevalence 
or incidence would be unreliable. Nevertheless, if estimated incidence is 0.3 per 100 000 PYR, this is 
very low. Adding the additional 70 to 85% which account for undiagnosed diabetes in many African 
countries [9], the numbers are still small. All new onset subjects in this study were diagnosed within 
the last eight months of the 24 months observational period, indicating a rising incidence. Local 
doctors supported this observation. Norway resides on the other end of the scale (36 per 100 000). The 
explanation for this unequal distribution remains unknown. 
Treatment 
At UUH, most children with T1D use insulin pump therapy, and the rest use MDI most commonly 
with a pen as administration form. In contrast, all children at UTHB use two injections per day and all 
of them use syringes. ISPAD recommends MDI or insulin pump therapy as the best options (equal 
regarding outcome and late complications) [47]. Two injections a day is acknowledged by ISPAD as a 
common insulin therapy regime in many parts of the world [47], though more frequently associated 
with poorer metabolic control and increased rate of complications [47]. ISPAD [47] and UTHB 
preferred intermediate insulin over long-acting insulin (in combination with rapid acting insulin) but 
due to not having intermediate insulin at the pharmacy, it is not used in the majority of the UTHB 
patients. 
Complications and mortality 
All patients (100%) had DKA at the time of diagnosis, compared to 25 % in Norway. Multiple reasons 
can explain this; people seek medical care later in the process, diagnostic misinterpretation and 
medical delay at health care centres/district hospitals. Poor prognosis of diabetes in Rwanda is 
reflected in the lower life expectancy: 35 years compared to 58 years in the background population 
[137]. Despite lack of reliable data, it is reasonable to assume that the life expectancy in Rwanda is 
shortened by more than 20 years due to diabetic complications. This is similar to life expectancy for a 
person with diabetes a few years after the introduction of insulin [8]. For a patient with T1D in 
Norway, survival rate in Norway was 98.9 % at ten years and 94.6% at 25 years [132]. In South Africa 
20 years mortality rate was 43% (57% survival rate) [89]. These figures may highlight the inadequate 
facilities available for care of children with T1D in developing compared to developed countries.  
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Chronic hyperglycemia increase the risk of complications 
Acute and probably also chronic complications of diabetes appear in Rwandan children, though 
complication rate is not registered. Short-term metabolic control is poor as shown by frequent 
hyperglycaemic episodes combined with great day to day BG variation. This finding is not surprising 
because the children do not always have insulin available and they do not self adjust the dose 
according to daily activities and food intake. Even when insulin is available, most of the patients lack 
the knowledge and means to administrate it correctly. In lack of means they take fewer doses of 
insulin to make it last longer.  
There was a high rate of pathological clinical manifestations in the re-hospitalized group, even though 
the duration of diabetes only was three to five years. Direct diabetes related complications were not 
acknowledged in the records, but multiple organ pathologies may indicate both direct and indirect 
complications of diabetes (figure 2). Chronic elevated blood sugar increases vulnerability to infectious 
diseases [140] and represents co morbidity. Reported symptoms are likely to be consistent with 
different pathologies as hepatitis (hepatomegaly, jaundice, dark urine, edema, acites, raised JVP) and 
pneumonia (lung crepitations, caugh) in several of these patients. Arrhythmia could be related to 
rheumatic heart disease (systolic murmur, gallop rhythm) which is relatively common in Rwanda or 
autonomic neuropathy. Some symptoms could also be related to kidney failure and the hepatorenal 
syndrome (kidney failure as a result of liver failure; edema, raised JVP).  
Insulin dose was adjusted during hospitalization where patients were relatively inactive and stayed in 
bed most of the day. Insulin requirements are known to be less during physical activity [141]. The 
daily routine for a Rwandan child, especially in the rural areas, includes long walks to school and 
heavy physical work on the fields. If the level of physical activity is higher at home this increases the 
risk of hypoglycaemic episodes. The patients are in general discharged with a higher BG than the 
recommended HbA1c under 7.5% would reflect (mean BG at discharge 12.0mmol/l equal to HbA1c at 
9%). This could be a ―calculated too high BG‖ due to the natural decrease in BG with increased level 
of activity at home or because a chronically too high BG was considered better than having many 
hypoglycaemic episodes. 
Insulin is not always available in Rwanda 
ISPAD recommends that all children with diabetes should at least have access to intermediate insulin 
combined with rapid acting/regular insulin; due to lack of availability, this is not possible in Rwanda. 
Insulin treatment is mainly based on long-acting insulin in combination with rapid acting regular 
insulin. Analogs have shown to reduce hypoglycaemic episodes and are considered better, but as they 
are 50-100% more expensive, it is understandable that implementation is not possible in Rwanda.  
In 2005, the president of the Association Rwandaise des Diabétiques, F. Gishoma, published an article 
[51] to highlight the main problems in diabetes care in Rwanda. He emphasized the importance of 
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availability of insulin and the need for international co-operation in making insulin available for 
developing countries that are not able to compete with international pricing. The average daily income 
of most Rwandan people is less than 1.0 EUR, a visit to the family doctor costs around 4.0-5.0 EUR 
and a visit to a specialist 8.0-10.0 EUR [51], equal of the average person‘s income for one week. 
These estimates are not unreasonable in 2011. A stay at the hospital causes a great financial burden 
upon a family. The cost for having a child in hospital is double; both the direct cost of 3000-4000RwF 
(4-5 EUR) (with health insurance) and the additional loss of income because one of the parents have to 
stay at the hospital together with the child. The hospital is in most cases far from the patient‘s home, 
making a combination impossible. UNICEF reported that 88 % of women in Rwanda have to walk for 
more than one hour to reach any kind of health care facility. Diabetes care was only offered at the 
university hospital which meant up to six hours travel (often by foot) to get there, each way. It is 
necessary with good health to walk for several hours to get to the OPC, thus, a selection has already 
been made.  
Gishoma [51] states that the excessive cost of insulin and diabetes supplies remains a major threat to 
the health of most people with diabetes. The withdrawal of animal insulin and the introduction of more 
expensive human insulins exacerbated the threat even further: a vial of human insulin 100 U/ml 
(~three months supply) costs around 15.0 EUR. He suggests that as a result, many people who should 
be taking carefully managed doses of insulin are forced to use inappropriate medication or seek care 
from traditional healers. In 2005, Australian ―Insulin for Life‖ and IDF Child Sponsorship Program 
offered their partnership to Rwanda. If these organizations still provide insulin today is not certain, but 
NovoNordisk project (Denmark) was established recently to provide free insulin supply. However, the 
patients still have to pay the OPC registration fee of 700RwF (~1EUR) once a month to get the insulin 
prescription.  
Closer cooperation between doctors and nurses can improve diabetes care 
Health systems in sub-Saharan Africa are currently organized for the treatment of acute rather than 
chronic conditions [142]. It is true that Rwanda needs more doctors instantly and that lack of means 
makes it difficult to prioritize expensive treatment for chronic diseases in a picture dominated by acute 
infectious diseases. There could be more efficient ways to tackle the escalating double burden of 
diseases in the future. In traditional diabetes care the doctor has all the responsibility and the nurses 
assist. This has been and still is the situation in some Norwegian hospitals today as well as in Rwanda. 
At UUH and several other hospitals, there has, however, been a shift towards making the nurses more 
independent in both teaching and follow-up of the diabetic children. In countries where there are few 
doctors per inhabitant, special trained diabetic nurses could lighten the burden on the doctor. 
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Quality of life 
Many children and adolescents find it difficult to cope emotionally with their condition. Diabetes 
causes them embarrassment, results in discrimination and limits social relationships. It is alarming that 
one of the diabetic children in Rwanda quit school because of diabetes. When a child gets a chronic 
disease such as diabetes, it affects not only the child itself, but the whole family in multiple ways; 
financially, socially and quality of life. Families with more than ten children are fairly common in 
Rwanda. If a huge part of the family‘s budget has to be spent on expensive diabetes treatment for one 
of the children, it is likely to believe that this could mean less food, less clothes and/or discontinued 
schooling for the siblings as well. In Norway, the major single cause of death in T1D subjects was due 
to violent deaths, including accidents, suicide and intoxication, indicating the psychological 
vulnerability and excessive burden it is to have diabetes.  
9.4. Conclusion 
Diabetes is still a neglected disease in Rwanda, though, greater awareness and knowledge is rising. As 
the situation is today, optimal diabetes care in depends on international funding of insulin and 
governmental action to put chronic diseases on the agenda. Construction of specialized diabetes clinics 
and trained health care personnel are needed as well as an official diabetes registry. Even though 
Norway has a solid skeleton of diabetes care, we still face many challenges and there is need for 
further improvement in glucose control and decreased complication rate. Other aspects of having 
diabetes need to be more thoroughly explored in the future, especially quality of life and psychological 
problems associated with diabetes, which have not been discussed thoroughly in this paper.  
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12.  Appendix 
1. Questionnaire - Diabetes Type 1 in children 
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QUESTIONNAIRE – DIABETES (T1D and T2D) IN CHILDREN: A 
GLOBAL PERSPECTIVE 
 
The questionnaire is designed to gather information about children with diabetes ≤ 15 years of age. 
The interview is in two parts. Each part should not last more than 1 hour. 
 
The first part is designed to map diabetes in children at a national or regional level. Each country has a 
number code (see list). The regions/counties/states are indicated by names.  The interviewer fills out 
this first part of the interview based on information available on the internet and other available 
sources. The information will then be quality assessed with the local informant. 
 
The second part is designed to map how children with diabetes are followed up at the local 
hospital/treatment centre. The interview contains multiple open, qualitative questions. The interview 
will therefore be tape-recorded. The tape recordings will be transcribed before the analysis takes place. 
 
The questionnaire does not ask for personal sensitive information. 
 
 
QUESTIONNAIRE – DIABETES IN CHILDREN ............................................................... 52 
PART 1 .................................................................................................................................... 54 
Incidence ............................................................................................................................. 54 
Prevalence ........................................................................................................................... 55 
Mortality .............................................................................................................................. 55 
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Pasientorganisations .............................................................................................................. 4 
Register for diabetes ............................................................................................................ 58 
Complications ...................................................................................................................... 58 
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Hospitalizations and number of beds .................................................................................. 59 
Diagnostics .......................................................................................................................... 60 
Treatment and follow up ..................................................................................................... 61 
Universitetet i Oslo 
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Treatment goals ................................................................................................................... 63 
Quality of life and mental health: ........................................................................................ 64 
Complications ...................................................................................................................... 65 
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Country (code): 
Region/county/state: 
Date: 
Informant: name/occupation  
Interview by: 
 
PART 1 
Incidence  
 
 
1. The annual incidence of the different types of diabetes in this country (enter the number 
and percentage) 
 Type 1 diabetes (T1D) 
 Type 2 diabetes (T2D) 
 Gestational diabetes 
 
2. The incidence of T1D and T2D among children under 15 years of age 
o The total incidence: 
o How is the distribution in the following groups of ages (estimated): 
o <5 years 
o 5-<10 years 
o 10-<15 years 
o > 15 years 
 
3. What is the gender distribution among children with T1D and T2D in the country? 
 
 
4. What are the overall proportions of the following ethnicities in this country: 
o White / European background (non-Hispanic whites)  
o Black / African background  
o Middle-East / North-African  
o Indian subcontinent  
o East-Asia 
o Middle- and South American (Hispanics)  
o Indigenous (specify) 
o Mixed (or unclassified) 
 
5. How many children with diabetes in this country are 
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o White / European background (non-Hispanic whites)  
o Black / African background  
o Middle-East / North-African  
o Indian subcontinent  
o East-Asia 
o Middle- and South American (Hispanics)  
o Indigenous (specify) 
o Mixed (or unclassified) 
Prevalence  
 
6. What is the prevalence of T1D and T2D among children in the following groups of age? 
o <5 years 
o 5-<10 years 
o 10-<15 years 
o ≥ 15 (adults) 
 
Mortality 
 
7. What is the average life expectancy in the country? 
o Women: 
o Men: 
 
 
8. What is the average life expectancy among patients diagnosed with T1D before   the age 
of 15?  
o Women: 
o Men: 
 
 
National health  
 
9. How many doctors per citizen? (This will differ depending on location; city, rural, town 
etc) 
 
10. Is there a geographical difference in availability of doctors? 
 
11.  What is the gross domestic product (GDP) of the county? 
 
12. What is the total expenditure on health as a percentage of the GDP? 
o Which proportion is financed by the public? 
o Which proportion is financed by private actors? 
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13. Which proportion of the national budget is spent on health? 
 
14. Does the public health care system finance the costs associated with diabetes medication 
and equipment? 
o Yes 
o No 
 
15. If the answer is yes on question 14, which medication is financed?  
o Insulin 
o Yes 
 _________% financed 
o No 
o Antidiabetic drugs 
o Yes 
 _________% financed 
o No 
 
          Glucagon 
o Yes 
               ____________% financed 
o No 
 
 
16. If yes on question 14, which of the following materials is financed  
o Syringes: 
o Needles: 
o Insulin pen: 
o Insulin pump: 
o Materials for the unconsciousness insulin pump: (needle, catheter, reservoir etc): 
o Home Blood Glucose meters: 
o Blood glucose test strips:  
o Finger-pricking devices: 
o Lancets for finger-pricking: 
o Continuous subcutaneous glucose monitoring devices: 
o Urine sticks to check for ketonuria: 
o Other:_____ 
 
17. If the answer is yes on question 14, does the patient have to pay anything? If so, how 
much? (%) 
o Syringes: 
o Needles: 
o Insulin pen: 
o Insulin pump: 
o Materials for the insulin pump: (needle, catheter, reservoir...): 
o Home Blood Glucose meters: 
o Blood glucose test strips:  
o Finger-pricking devices: 
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o Lancets for finger-pricking: 
o Continuous subcutaneous glucose monitoring devices: 
o Urine sticks to check for ketonuria: 
o Other:_____ 
 
18. How brings the child to their check-ups? 
o Mum 
o Dad 
o Other:_______ (specify) 
 
19. Are there any laws/public rights for parents to get extra time off work to take their 
children to check ups?  
o Yes 
o No 
 
20. Are parents with chronic ill children allowed to take additional days off compared to the 
general population?  
o Yes (________number of additional days) 
o No 
 
21. Are there national guidelines for the management of children with T1D and T2D? 
o Yes 
o No 
 
 
 
Patient organizations 
 
 
22. Are there any national organizations for patients with diabetes? 
o Yes 
o For children? 
o For children and adults? 
o For adults only? 
o No 
 
23. Are there any local organizations for patients with T1D? 
o Yes 
o For children? 
o For children and adults? 
o For adults only? 
o No 
 
Comment:  
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24. What do the patient organizations offer the children and their parents? 
o Websites  
o Telephone 
o Courses 
o Information meetings 
o Holiday offers 
o Other:_________ 
 
Register for diabetes 
 
25. Is there a national diabetes register? 
o Yes, for children 
o Yes, for adults 
o Yes, for adults and children 
o No  
 
26. If yes, what data is registered? 
 
 
Complications 
 
27. What is the incidence of acute diabetes complications among children under 15 years of 
age? 
o Diabetic ketoacidosis (with hospitalization)  
o Grave hypoglycemia (unconscious with or without convulsions)  
 
28. What is the incidence of late diabetes complications among children under 15 years of 
age? (estimated percentage) 
o Retinopathy 
o Nefropathy 
o Nevropathy 
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Country (code): 
Region/county/state: 
Local treatmentcenter (name and type): 
Date: 
Informant: name/occupation  
Interview by: 
 
PART 2 
 
 
Hospitalizations and number of hospital beds 
 
29. How many children <15 years with diabetes are admitted to hospital annually in the 
following wards (The total number of hospitalizations including rehospitalization) 
o Pediatric ward  
o Adolescens ward 
o Internal medical ward 
 
 
30. To what age are the children managed in the pediatric wards?_____ 
 
31. If there is an adolescent department, when do the children start attending and how long 
can they attend there? 
 
32. What is the maximum number of beds in the ward? _________ 
 
33. How often has the ward been full during the last 6 months? (regardless of the reason for the 
hospitalisation) 
 
34. How many children with diabetes are followed up at the local hospital today? 
 
35. How is the gender distribution among the children that are followed up at the local 
hospital? 
 
36. Who takes over the responsibility for the treatment and follow-up after the diagnosis of 
diabetes? 
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o Specialist __________ (which type) 
o General practitioner (GP) 
o Other :________ 
 
 
 
Diagnostics 
 
37. Who usually make the diagnosis? 
o General practice 
o Specialised health service 
o Nurse 
o Other:_________ 
 
38.  What is the average age at diagnosis? 
 
39. What are the classical symptoms that make the patient and his or her parents contact a 
doctor? 
 
40.  Which diagnostic criteria have to be fulfilled to make the diagnose of diabetes? 
 
o International guidelines; ISPAD (Blood glucose) 
o Other guidelines:__________________ 
 
41. Where are recently diagnosed juvenile diabetics treated the first time? 
o  Out-patients clinic 
o Hospital ward with beds 
 
42. If the patient is admitted to hospital, what is the average length of stay? 
 
43. Which diagnostic criteria do you use for DKA? 
o Hyperglycemia 
o Standard Bicarbonate (< 15 mmol) 
o pH (< 7,3) 
o Urine ketons 
 
44. What proportion of children has DKA at diagnosis? 
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Treatment and follow up 
 
45. Who participates in the treatment and follow up of children with diabetes? 
o Nurse 
o Doctor 
o School nurse 
o Social worker 
o Nutritionist  
o Psychologist 
o Other:___________ 
o Multidisciplinary team 
 
46. Does the child with diabetes have one particular contact person? If yes, specify: 
o Yes:___________ 
o No 
 
47. When the diagnosis is made who is responsible for the follow-up? 
o Specialist (doctor / diabetologist) 
o Hospital doctor 
o Nurse 
o General practitioner  
o Other:_________ 
 
48.  Who are educated (at the time of the diagnosis, and after discharge)? 
o The child 
o Parents 
o School  
o School nurse 
o Nursery 
o Activity leaders/coaches 
o Others:___________ 
o No one 
 
49. Does the hospital have access to interpreters when they have patients that do not speak/understand 
English? 
 
50. How is the education organized? 
o Training in groups 
o Individual training 
o A combination of both 
 
51. When is a new education organized? (re-education) 
 
52.  Is carbohydrate counting used systematically when calculating the insulin bolus in relation to 
food? 
 
 
53. How is the education organized? 
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o Training in groups 
o Individual training 
o A combination of a and 
 
Comment: 
 
 
 
54. How much do parents participate in the treatment and follow up? 
 
55. Do the adolescents get contraceptive counseling? 
o Yes (comment;)_____________ 
o No 
 
56. Have you experienced unintended pregnancies in this group of patients? 
o Yes (how many? what are the characteristics of these patients; ethnicity, socioeconomic 
status etc?) 
o No 
 
57. What types of treatment/treatment regimens are available for children with diabetes at the local 
hospital? 
o Syringes 
o Needles 
o Insulin pen 
o Insulin pump 
o Continuous Subcutaneous Glucose Monitoring  
o Others:_______________ 
o None 
 
58. How many patients use multi injection (insulin > 3 times a day) therapy? 
 
59. What proportion of the patients (in number and percentage) follow the different treatment 
regimens listed 
o Insulin pump: 
o Others: 
o None:? 
 
60. Among the children under multi injection therapy what type of insulin preparations are used? (%) 
o Premixed insulin preparations  
o Intermediate-acting insulin + rapid-acting insulin 
o Analogues 
o Which combinations: ____________ 
o Are there any different strategies for insulin therapy concerning the child´s age? 
 
 
 
61. Who does the patient and his or her parents contact if the child is acute ill? 
o Specialist  
o Contact person 
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o GP 
o Emergency room 
o Other:__________ 
 
Treatment goals 
 
62. Are the ISPAD treatment goals adhered to? 
o Yes 
o No  
o If no, which guidelines are used______________ 
 
63.  What are the treatment goals 
o HbA1c < 7,5 % 
o Other:________ 
 
 
64. What proportions (%) of patients achieve the treatment goals? 
 
65. How often do the children attend diabetes health check ups?____________________ 
 
66. What proportions (%) of the patients attend their appointment? 
 
 
o Most patients 
o 50 % 
o Only a few 
 
 
67. Who does not attend? Why? What are the characteristics of these patients? 
 
 
 
 
 
 
68. Is there a screening program for autoimmune diseases? 
o Yes 
o No   
 
69. If yes, witch diseases are included in the screening 
o Celiac disease 
o Hypothyroidism / hyperthyroidism 
o Others:___________________ 
 
70. If yes, how often is the screening performed 
o At each check up 
o Annually  
o Other:_____________________ 
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71. Are there any screening program concerning late diabetes complications among children with 
diabetes? 
o Yes 
o No 
 
 
72. If yes, what kind of late diabetes complications are included in the screening program among 
children with diabetes? And which methods are used in the screening 
o Retinopathy:___________________________________________ 
o Nephropathy;____________________________________________ 
o Neuropathy:__________________________________________ 
o Angiopathy:__________________________________ 
o Others:__________________________ 
 
73. If yes on question 70, how often is the screening performed 
o At every check up: 
o Annually: 
o Other: _______ 
 
 
 
 
Quality of life and mental health: 
 
 
74. What assistance do the children with diabetes and their parents  receive in relation to: 
 
o School 
 
o Hobbies   
 
o Sports 
 
 
75. Are there social activities arranged for the children and their parents?  
 
76. What kind of social activities are arranged? And who organises them? 
 
 
 
77. Have you conducted/do you conduct research on the quality of life in the children with diabetes? 
 
o Yes 
 If yes, can you elaborate 
 
 
o No 
 
78.  Are intoxicants a problem among children with T1D? 
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o Yes 
o What kind of intoxicant? 
o What are the characteristics of these patients (gender, ethnicity, socioeconomic 
status etc) 
o No 
 
Comment: 
 
 
Complications 
 
 
79. What is the incidence (percentage) of acute diabetes complications among children with T1D 
under the age of 15? 
o Diabetic ketoacidosis 
o Hypoglycemic shock with unconsciousness and/or convulsions 
o Other:___________ 
 
80. What is the incidence (%) of long-term complications among children under the age of 15 years? 
And how old are they? 
o Retinopathy: 
How many have been treated with laser? 
o Nephropathy: 
o Neuropathy: 
o Hypertension  
How many get anti hypertension treatment? 
 
81. What is the incidence (%) of long-term complication among adults who got the diagnose of 
diabetes before they turned 15 years? 
 
      The following must be discussed: 
o How old were the patients when they where diagnosed with diabetes? 
o How many years diabetes duration at onset of the late complication? 
 
o Retinopathy: 
o Nephropathy: 
o Neuropathy: 
 
 
82. Is overweight a problem among children with diabetes? 
o If yes: 
o Are there any differences between gender, ethnicity, socioeconomic background etc? 
o In which group is the prevalence of overweight highest? 
o What kind of prevention and treatment regimens does the hospital have? 
o Are the treatment regimens effective? 
o Do children with overweight in practice have significant more complications than children 
with normal weight? 
o Are there other problems related to overweight and diabetes? 
 
